

DAVITA HEALTHCARE PARTNERS INC.

Form 10-Q

August 01, 2014

[Table of Contents](#)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

For the Quarterly Period Ended June 30, 2014

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-14106

DAVITA HEALTHCARE PARTNERS INC.

2000 16th Street

Denver, CO 80202

Telephone number (303) 405-2100

Delaware
(State of incorporation)

51-0354549
(I.R.S. Employer

Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of July 29, 2014, the number of shares of the Registrant's common stock outstanding was approximately 214.8 million shares and the aggregate market value of the common stock outstanding held by non-affiliates based upon the closing price of these shares on the New York Stock Exchange was approximately \$15.3 billion.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

INDEX

	Page No.
PART I. FINANCIAL INFORMATION	
Item 1.	
<u>Condensed Consolidated Financial Statements:</u>	
<u>Consolidated Statements of Income for the three and six months ended June 30, 2014 and June 30, 2013</u>	1
<u>Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2014 and June 30, 2013</u>	2
<u>Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013</u>	3
<u>Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and June 30, 2013</u>	4
<u>Consolidated Statements of Equity for the six months ended June 30, 2014 and for the year ended December 31, 2013</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6
Item 2.	
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	41
Item 3.	
<u>Quantitative and Qualitative Disclosures about Market Risk</u>	63
Item 4.	
<u>Controls and Procedures</u>	65
PART II. OTHER INFORMATION	
Item 1.	
<u>Legal Proceedings</u>	66
Item 1A.	
<u>Risk Factors</u>	66
Item 2.	
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	95
Item 6.	
<u>Exhibits</u>	96
<u>Signature</u>	98

Note: Items 3, 4 and 5 of Part II are omitted because they are not applicable.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.
CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(dollars in thousands, except per share data)

	Three months ended		Six months ended	
	June 30,		June 30,	
	2014	2013	2014	2013
Patient service revenues	\$ 2,187,249	\$ 2,048,651	\$ 4,301,347	\$ 4,028,524
Less: Provision for uncollectible accounts	(88,052)	(72,191)	(171,249)	(142,248)
Net patient service revenues	2,099,197	1,976,460	4,130,098	3,886,276
Capitated revenues	799,369	710,074	1,586,934	1,472,689
Other revenues	273,923	185,139	498,233	342,290
Total net revenues	3,172,489	2,871,673	6,215,265	5,701,255
Operating expenses and charges:				
Patient care costs and other costs	2,246,538	2,014,320	4,426,310	3,975,211
General and administrative	298,636	268,110	582,697	552,520
Depreciation and amortization	145,907	130,589	288,486	256,498
Provision for uncollectible accounts	3,208	1,260	5,719	2,138
Equity investment income	(6,095)	(7,649)	(13,467)	(17,016)
Loss contingency reserve				300,000
Contingent earn-out obligation adjustment		(56,977)		(56,977)
Total operating expenses and charges	2,688,194	2,349,653	5,289,745	5,012,374
Operating income	484,295	522,020	925,520	688,881
Debt expense	(106,132)	(108,096)	(212,467)	(213,913)
Debt refinancing charges	(97,548)		(97,548)	
Other income (loss), net	1,693	(1,374)	3,391	(776)
Income from continuing operations before income taxes	282,308	412,550	618,896	474,192
Income tax expense	100,887	129,192	225,738	144,336
Income from continuing operations	181,421	283,358	393,158	329,856
Discontinued operations:				
Loss from operations of discontinued operations, net of tax				(139)
Gain on disposal of discontinued operations, net of tax				13,375

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Net income	181,421	283,358	393,158	343,092
Less: Net income attributable to noncontrolling interests	(33,738)	(28,982)	(62,186)	(58,552)

Net income attributable to DaVita HealthCare Partners Inc.	\$ 147,683	\$ 254,376	\$ 330,972	\$ 284,540
--	------------	------------	------------	------------

Earnings per share:

Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	\$ 0.70	\$ 1.21	\$ 1.56	\$ 1.29
---	---------	---------	---------	---------

Basic net income per share attributable to DaVita HealthCare Partners Inc.	\$ 0.70	\$ 1.21	\$ 1.56	\$ 1.36
--	---------	---------	---------	---------

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	\$ 0.68	\$ 1.18	\$ 1.53	\$ 1.26
---	---------	---------	---------	---------

Diluted net income per share attributable to DaVita HealthCare Partners Inc.	\$ 0.68	\$ 1.18	\$ 1.53	\$ 1.33
--	---------	---------	---------	---------

Weighted average shares for earnings per share:

Basic	212,258,994	209,797,334	211,817,893	209,385,380
-------	-------------	-------------	-------------	-------------

Diluted	216,720,944	214,849,164	216,420,713	214,490,452
---------	-------------	-------------	-------------	-------------

Amounts attributable to DaVita HealthCare Partners Inc.:

Income from continuing operations	\$ 147,683	\$ 254,376	\$ 330,972	\$ 271,291
Discontinued operations				13,249

Net income	\$ 147,683	\$ 254,376	\$ 330,972	\$ 284,540
------------	------------	------------	------------	------------

See notes to condensed consolidated financial statements.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands)

	Three months ended		Six months ended	
	June 30,		June 30,	
	2014	2013	2014	2013
Net income	\$ 181,421	\$ 283,358	\$ 393,158	\$ 343,092
Other comprehensive income (loss), net of tax:				
Unrealized losses on interest rate swap and cap agreements:				
Unrealized (loss) gain on interest rate swap and cap agreements	(5,209)	11,685	(7,714)	9,316
Reclassifications of net swap and cap agreements realized loss into net income	4,997	3,462	8,356	5,969
Unrealized gains on investments:				
Unrealized gain on investments	578	101	909	719
Reclassification of net investment realized gains into net income			(207)	(94)
Foreign currency translation adjustments	1,939	(1,841)	1,967	(3,947)
Other comprehensive income	2,305	13,407	3,311	11,963
Total comprehensive income	183,726	296,765	396,469	355,055
Less: Comprehensive income attributable to noncontrolling interests	(33,738)	(28,982)	(62,186)	(58,552)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 149,988	\$ 267,783	\$ 334,283	\$ 296,503

See notes to condensed consolidated financial statements.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****CONSOLIDATED BALANCE SHEETS****(unaudited)****(dollars in thousands, except per share data)**

	June 30, 2014	December 31, 2013
ASSETS		
Cash and cash equivalents	\$ 1,420,973	\$ 946,249
Short-term investments	63,835	6,801
Accounts receivable, less allowance of \$244,878 and \$237,143	1,550,252	1,485,163
Inventories	99,650	88,805
Other receivables	455,620	349,090
Other current assets	164,591	176,414
Income tax receivable	6,965	10,315
Deferred income taxes	399,361	409,441
Total current assets	4,161,247	3,472,278
Property and equipment, net of accumulated depreciation of \$1,936,494 and \$1,778,259	2,290,844	2,189,411
Intangibles, net of accumulated amortization of \$565,839 and \$483,773	2,022,875	2,024,373
Equity investments	42,842	40,686
Long-term investments	87,614	79,557
Other long-term assets	66,106	79,598
Goodwill	9,254,043	9,212,974
	\$ 17,925,571	\$ 17,098,877
LIABILITIES AND EQUITY		
Accounts payable	\$ 405,751	\$ 435,465
Other liabilities	465,242	464,422
Accrued compensation and benefits	626,617	603,013
Medical payables	304,551	287,452
Loss contingency reserve	397,000	397,000
Senior notes (6 ³ / ₈ % Senior Notes)	291,907	
Current portion of long-term debt	117,080	274,697
Total current liabilities	2,608,148	2,462,049
Long-term debt	8,390,578	8,141,231
Other long-term liabilities	386,033	380,337
Deferred income taxes	823,745	812,419
Total liabilities	12,208,504	11,796,036

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Commitments and contingencies		
Noncontrolling interests subject to put provisions	760,242	697,300
Equity:		
Preferred stock (\$0.001 par value, 5,000,000 shares authorized; none issued)		
Common stock (\$0.001 par value, 450,000,000 shares authorized; 214,759,091 and 213,163,248 shares issued and outstanding at June 30, 2014 and at December 31, 2013, respectively)	215	213
Additional paid-in capital	1,089,929	1,070,922
Retained earnings	3,694,961	3,363,989
Accumulated other comprehensive income (loss)	666	(2,645)
Total DaVita HealthCare Partners Inc. shareholders equity	4,785,771	4,432,479
Noncontrolling interests not subject to put provisions	171,054	173,062
Total equity	4,956,825	4,605,541
	\$ 17,925,571	\$ 17,098,877

See notes to condensed consolidated financial statements.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

	Six months ended June 30,	
	2014	2013
Cash flows from operating activities:		
Net income	\$ 393,158	\$ 343,092
Adjustments to reconcile net income to cash provided by operating activities:		
Loss contingency reserve		300,000
Depreciation and amortization	288,470	256,382
Debt refinancing charges	97,548	
Stock-based compensation expense	29,699	32,266
Tax benefits from stock award exercises	42,110	36,524
Excess tax benefits from stock award exercises	(30,238)	(28,442)
Deferred income taxes	13,826	(102,039)
Equity investment income, net	2,257	(496)
Other non-cash (income) charges and loss on disposal of assets	22,861	(69,050)
Changes in operating assets and liabilities, other than from acquisitions and divestitures:		
Accounts receivable	(65,079)	(17,829)
Inventories	(10,731)	924
Other receivables and other current assets	(95,580)	(65,349)
Other long-term assets	2,158	(1,220)
Accounts payable	(46,022)	(94,894)
Accrued compensation and benefits	19,912	(14,279)
Other current liabilities	31,970	82,905
Income taxes	2,886	(9,182)
Other long-term liabilities	(17,707)	36,713
Net cash provided by operating activities	681,498	686,026
Cash flows from investing activities:		
Additions of property and equipment, net	(278,593)	(258,396)
Acquisitions	(98,442)	(152,112)
Proceeds from asset and business sales	215	64,363
Purchase of investments available for sale	(6,117)	(3,286)
Purchase of investments held-to-maturity	(121,333)	(1,032)
Proceeds from sale of investments available for sale	1,277	1,091
Proceeds from sale of investments held to maturity	64,561	1,376
Purchase of intangible assets and equity investment	(4,760)	(7)

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Distributions received on equity investments	337	116
Net cash used in investing activities	(442,855)	(347,887)
Cash flows from financing activities:		
Borrowings	33,136,743	33,445,567
Payments on long-term debt and other financing costs	(32,788,307)	(33,696,216)
Deferred financing costs and debt redemption costs	(106,937)	(716)
Distributions to noncontrolling interests	(65,818)	(65,206)
Stock award exercises and other share issuances, net	7,274	8,819
Excess tax benefits from stock award exercises	30,238	28,442
Contributions from noncontrolling interests	28,265	20,132
Proceeds from sales of additional noncontrolling interests	933	5,903
Purchases from noncontrolling interests	(5,743)	(474)
Net cash provided by (used in) financing activities	236,648	(253,749)
Effect of exchange rate changes on cash and cash equivalents	(567)	(234)
Net increase in cash and cash equivalents	474,724	84,156
Cash and cash equivalents at beginning of the year	946,249	533,748
Cash and cash equivalents at end of the year	\$ 1,420,973	\$ 617,904

See notes to condensed consolidated financial statements.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.
CONSOLIDATED STATEMENTS OF EQUITY
(unaudited)
(dollars and shares in thousands)

	Non- controlling interests subject to put provisions	Common stock	DaVita HealthCare Partners Inc. Shareholders				Equity Accumulated other comprehensive income (loss)	Total	Non- controlling interests not subject to put provisions	
			Additional paid-in capital	Retained earnings	Treasury stock					
Balance at December 31, 2012	\$ 580,692	269,725	\$ 270	\$ 1,208,665	\$ 3,731,835	(58,728)	\$ (1,162,336)	\$ (15,297)	\$ 3,763,137	\$ 153,784
Comprehensive income:										
Net income	78,215			633,446					633,446	45,544
Other comprehensive income							12,652		12,652	
Stock purchase shares issued		238		12,817					12,817	
Stock unit shares issued		7		(3,286)		164	3,247		(39)	
Stock-settled RSR shares issued		313		(29,025)		1,444	28,561		(464)	
Stock-based compensation expense				59,998					59,998	
Less tax benefits from stock awards exercised				36,197					36,197	
Contributions to non-controlling interests	(80,353)									(58,974)
Contributions from non-controlling interests	22,053									14,944

es and assumptions of additional controlling interests	23,642			(1,442)				(1,442)	10,77	
urchases from controlling interests	(512)			(3,119)				(3,119)	(14	
piration of option and er	(7,141)								7,14	
classification changes in fair value of controlling interests	80,704			(80,704)				(80,704)		
treasury stock reimbursement		(57,120)	(57)	(129,179)	(1,001,292)	57,120	1,130,528			
Balance at December 31, 2013	\$ 697,300	213,163	\$ 213	\$ 1,070,922	\$ 3,363,989		\$	\$ (2,645)	\$ 4,432,479	\$ 173,00
Comprehensive income:										
Net income	43,590				330,972				330,972	18,59
Other comprehensive income								3,311	3,311	
Stock unit shares issued		290		(27)					(27)	
Stock-settled RSU shares vested		1,306	2	(2)						
Stock-based compensation expense				29,699					29,699	
Less tax benefits from stock awards exercised				30,238					30,238	
Contributions to controlling interests	(41,733)									(24,08
Contributions from controlling interests	18,240									10,02
es and assumptions of additional controlling	918			15					15	

Interests										
Acquisition and										
Interests from										
controlling										
Interests	(446)			1,247				1,247		(6,541)
Adjustment in										
ownership										
Interests				210				210		
Changes in fair										
value of										
controlling										
Interests	42,373			(42,373)				(42,373)		
Balance at										
March 31, 2014	\$ 760,242	214,759	\$ 215	\$ 1,089,929	\$ 3,694,961	\$	\$	666	\$ 4,785,771	\$ 171,051

See notes to condensed consolidated financial statements.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(dollars and shares in thousands, except per share data)

Unless otherwise indicated in this Quarterly Report on Form 10-Q the Company, we, us, our and similar terms refer to DaVita HealthCare Partners Inc. and its consolidated subsidiaries.

1. Condensed consolidated interim financial statements

The condensed consolidated interim financial statements included in this report are prepared by the Company without audit. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve the accrual of an estimated loss contingency reserve and its impact on the Company's income taxes, revenue recognition and accounts receivable, impairments of long-lived assets, fair value estimates, accounting for income taxes, variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, long-term incentive program compensation and medical liability claims. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of the operating results for the full year. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013. Prior year balances and amounts have been reclassified to conform to the current year presentation. The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and has included all necessary disclosures.

2. Earnings per share

Basic net income per share is calculated by dividing net income attributable to the Company, adjusted for any change in noncontrolling interests redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units (under the treasury stock method).

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows:

	Three months ended June 30,		Six months ended June 30,	
	2014	2013	2014	2013
Basic:				
Income from continuing operations attributable to DaVita HealthCare Partners Inc.	\$ 147,683	\$ 254,376	\$ 330,972	\$ 271,291
Increase in noncontrolling interests redemption rights in excess of fair value		(259)		(259)
Income from continuing operations for basic earnings per share calculation	\$ 147,683	\$ 254,117	\$ 330,972	\$ 271,032
Discontinued operations attributable to DaVita HealthCare Partners Inc.				13,249
Net income attributable to DaVita HealthCare Partners Inc. for basic earnings per share calculation	\$ 147,683	\$ 254,117	\$ 330,972	\$ 284,281
Weighted average shares outstanding during the period	214,451	211,986	214,010	211,574
Vested stock units	2	5	2	5
Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger	(2,194)	(2,194)	(2,194)	(2,194)
Weighted average shares for basic earnings per share calculation	212,259	209,797	211,818	209,385
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	\$ 0.70	\$ 1.21	\$ 1.56	\$ 1.29
Basic income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.	\$	\$	\$	\$ 0.07
Basic net income per share attributable to DaVita HealthCare Partners Inc.	\$ 0.70	\$ 1.21	\$ 1.56	\$ 1.36

Diluted:

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Income from continuing operations attributable to DaVita HealthCare Partners Inc.	\$ 147,683	\$ 254,376	\$ 330,972	\$ 271,291
Increase in noncontrolling interests redemption rights in excess of fair value		(259)		(259)
Income from continuing operations for diluted earnings per share calculation	\$ 147,683	\$ 254,117	\$ 330,972	\$ 271,032
Discontinued operations attributable to DaVita HealthCare Partners Inc.				13,249
Net income attributable to DaVita HealthCare Partners Inc. for diluted earnings per share calculation	\$ 147,683	\$ 254,117	\$ 330,972	\$ 284,281
Weighted average shares outstanding during the period	214,451	211,986	214,010	211,574
Vested stock units	2	5	2	5
Assumed incremental shares from stock plans	2,268	2,858	2,409	2,911
Weighted average shares for diluted earnings per share calculation	216,721	214,849	216,421	214,490
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	\$ 0.68	\$ 1.18	\$ 1.53	\$ 1.26
Diluted income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.	\$	\$	\$	\$ 0.07
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	\$ 0.68	\$ 1.18	\$ 1.53	\$ 1.33
Anti-dilutive stock-settled awards excluded from calculation ⁽¹⁾	990	4,520	1,995	3,353

(1) Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

3. Accounts receivable

Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of the Company's accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by government payors, like Medicare, the Company receives 80% of the payment directly from Medicare as established under the government's bundled payment system, in the case of dialysis services receivables, and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company's estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. Approximately 1% of the Company's net accounts receivable are associated with patient pay and it is the Company's policy to record an allowance for 100% of these outstanding dialysis accounts receivable balances when those amounts due are outstanding for more than four months.

During the six months ended June 30, 2014, the Company's allowance for doubtful accounts increased by approximately \$7,735. This was mainly due to an increase relating to the U.S. dialysis and related lab services, primarily as a result of additional non-covered Medicare write-offs. There were no unusual transactions impacting the allowance for doubtful accounts.

4. Investments in debt and equity securities and other investments

Based on the Company's intentions and strategy concerning investments in debt securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values, including those of mutual funds, common stock and other debt securities, are classified as available-for-sale and recorded at fair value.

The Company's investments in securities consist of the following:

June 30, 2014	December 31, 2013
Total	Total

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

	Held to maturity	Available for sale		Held to maturity	Available for sale	
Certificates of deposit and money market funds due within one year	\$ 62,374	\$	\$ 62,374	\$ 5,601	\$	\$ 5,601
Investments in mutual funds and common stock		25,685	25,685		19,421	19,421
	\$ 62,374	\$ 25,685	\$ 88,059	\$ 5,601	\$ 19,421	\$ 25,022
Short-term investments	\$ 62,374	\$ 1,461	\$ 63,835	\$ 5,601	\$ 1,200	\$ 6,801
Long-term investments		24,224	24,224		18,221	18,221
	\$ 62,374	\$ 25,685	\$ 88,059	\$ 5,601	\$ 19,421	\$ 25,022

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

The cost of the certificates of deposit and money market funds at June 30, 2014 and December 31, 2013 approximates their fair value. As of June 30, 2014 and December 31, 2013, the available-for-sale investments included \$6,161 and \$5,096 of gross pre-tax unrealized gains, respectively. During the six months ended June 30, 2014, the Company recorded gross pre-tax unrealized gains of \$1,405, or \$909 after tax, in other comprehensive income associated with changes in the fair value of these investments. During the six months ended June 30, 2014, the Company sold investments in mutual funds for net proceeds of \$1,277 and recognized a pre-tax gain of \$340, or \$207 after-tax, which was previously recorded in other comprehensive income. During the six months ended June 30, 2013, the Company sold investments in mutual funds for net proceeds of \$1,091 and recognized a pre-tax gain of \$155, or \$94 after-tax, which was previously recorded in other comprehensive income.

The investments in mutual funds classified as available-for-sale are held within a trust to fund existing obligations associated with several of the Company's non-qualified deferred compensation plans.

As of June 30, 2014, the Company held \$5,000 of preferred stock in a privately held company that is accounted for under the cost method as this investment does not have a readily determinable fair value.

Certain HCP entities are required to maintain minimum cash balances in order to comply with regulatory requirements in conjunction with medical claim reserves. As of June 30, 2014, this minimum cash balance was approximately \$58,000.

5. Goodwill

Changes in goodwill by reportable segments were as follows:

	Six months ended June 30, 2014			
	U.S. dialysis and related lab services	HCP	Other-ancillary services and strategic initiatives	Consolidated total
Balance at December 31, 2013	\$ 5,469,473	\$ 3,516,162	\$ 227,339	\$ 9,212,974
Acquisitions	2,915	38,639	820	42,374
Other adjustments		(2,277)	972	(1,305)
Balance at June 30, 2014	\$ 5,472,388	\$ 3,552,524	\$ 229,131	\$ 9,254,043

Year ended December 31, 2013

	U.S. dialysis and related lab services	HCP	Other-ancillary services and strategic initiatives	Consolidated total
Balance at December 31, 2012	\$ 5,309,152	\$ 3,506,571	\$ 137,027	\$ 8,952,750
Acquisitions	163,037	17,833	90,397	271,267
Divestitures	(2,728)			(2,728)
Other adjustments	12	(8,242)	(85)	(8,315)
Balance at December 31, 2013	\$ 5,469,473	\$ 3,516,162	\$ 227,339	\$ 9,212,974

Each of the Company's operating segments described in Note 16 to these condensed consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within our international operations segments is considered a separate reporting unit.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.

The Company has applied a similar aggregation to the HCP operations in each region, to the vascular access service centers in its vascular access services reporting unit, to the physician practices in its physician services reporting unit, and to the dialysis centers within each sovereign international jurisdiction. For the Company's additional operating segments, no component below the operating segment level is considered a discrete business and therefore these operating segments directly constitute individual reporting units.

HCP's current and expected future operating results have eroded recently, primarily as a result of reductions in its Medicare Advantage reimbursement rates. As a result, the Company has determined that two of its HCP reporting units, HCP California and HCP Nevada, are at risk of goodwill impairment. HCP California and HCP Nevada have goodwill of \$2,511,477 and \$517,618, respectively.

The Company obtained preliminary third-party valuations of these two businesses as of June 30, 2014, noting that the estimated fair values of HCP California and HCP Nevada exceed their total carrying values by approximately 6.0% and 10.9%, respectively. Further reductions in HCP's reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future.

For example, a sustained, long-term reduction of 3% in operating income for HCP California and HCP Nevada could reduce their estimated fair values by up to 3.1% and 2.9%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California and HCP Nevada by up to 7.7% and 6.1%, respectively.

During the first six months of 2014, the Company did not record any goodwill impairment charges. Except as described above, none of the goodwill associated with the Company's various other reporting units was considered at risk of impairment as of June 30, 2014. Since the dates of the Company's last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in circumstances that have affected the Company's businesses. However, these did not cause management to believe it is more likely than not that the fair value of any of its reporting units would be less than its carrying amount.

6. Health care costs payable

The health care costs shown in the following table include estimates for the cost of professional medical services provided by non-employed physicians and other providers, as well as inpatient and other ancillary costs for all

markets, where state regulation allows for the assumption of global risk. Health care costs payable are included in medical payables.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

The following table shows the components of changes in the health care costs payable for the six months ended June 30, 2014:

	Six months ended June 30, 2014
Health care costs payable, beginning of the period	\$ 172,310
Add: Components of incurred health care costs	
Current year	775,604
Prior years	5,602
Total incurred health care costs	781,206
Less: Claims paid	
Current year	589,968
Prior years	153,223
Total claims paid	743,191
Health care costs payable, end of the period	\$ 210,325

Our prior year estimates of health care costs payable increased by \$5,602 resulting from certain medical claims being settled for amounts more than originally estimated. When significant increases (decreases) in prior-year health care cost estimates occur that we believe significantly impact our current year operating results, we disclose that amount as unfavorable (favorable) development of prior-year's health care cost estimates. Actual claim payments for prior year services have not been materially different from our year-end estimates.

7. Income taxes

As of June 30, 2014, the Company's total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is \$60,372, of which \$32,945 would impact the Company's effective tax rate if recognized. This balance represents a decrease of \$166 from the December 31, 2013 balance of \$60,538.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At June 30, 2014 and December 31, 2013, the Company had approximately \$11,969 and \$10,742, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.

As of June 30, 2014, it is reasonably possible that \$27,427 of unrecognized tax benefits may be recognized within the next 12 months, primarily related to the filing of tax accounting method changes which will not impact the Company's effective tax rate.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

8. Long-term debt

Long-term debt was comprised of the following:

	June 30, 2014	December 31, 2013
Senior Secured Credit Facilities:		
New Term Loan A	\$ 1,000,000	\$
New Term Loan B	3,500,000	
Prior Term Loan A		800,000
Prior Term Loan A-3		1,282,500
Prior Term Loan B		1,697,500
Prior Term Loan B-2		1,633,500
Senior notes	4,066,907	2,800,000
Acquisition obligations and other notes payable	66,511	67,352
Capital lease obligations	183,647	152,751
Total debt principal outstanding	8,817,065	8,433,603
Discount on long-term debt	(17,500)	(17,675)
	8,799,565	8,415,928
Less current portion	(408,987)	(274,697)
	\$ 8,390,578	\$ 8,141,231

Classification of long-term debt at June 30, 2014 was as follows:

Senior notes	\$ 291,907
Current portion	117,080
Total current portion	408,987
Long-term debt	8,390,578
	\$ 8,799,565

Scheduled maturities and pay-outs of long-term debt at June 30, 2014 were as follows:

2014 (remainder of the year, including the 6 ³ / ₈ % Senior Notes)	347,712
2015	112,182
2016	115,645
2017	141,972
2018	153,282
2019	727,238
Thereafter	7,219,034

During the first six months of 2014, the Company made mandatory principal payments under its then existing Senior Secured Credit Facilities (before entering into a new senior secured credit agreement and repaying all outstanding amounts under the then existing Senior Secured Credit Facilities) totaling \$37,500 on the Term Loan A, \$16,875 on the Term Loan A-3, \$4,375 on the Term Loan B and \$4,125 on the Term Loan B-2.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

In June 2014, the Company entered into a \$5,500,000 senior secured credit agreement (the New Credit Agreement). The New Credit Agreement consists of a five year Revolving Credit Facility in the aggregate principal amount of \$1,000,000 (the New Revolver), a five year Term Loan A facility in the aggregate principal amount of \$1,000,000 (the New Term Loan A) and a seven year Term Loan B facility in the aggregate principal amount of \$3,500,000 (the New Term Loan B and collectively with the New Revolver and the New Term Loan A, the New Loans). In addition, the Company can increase the existing revolving commitments and enter into one or more incremental term loan facilities in an amount not to exceed the sum of \$1,500,000 (less the amount of other permitted indebtedness incurred or issued in reliance on such amount), plus an amount of indebtedness such that the senior secured leverage ratio is not in excess of 3.50 to 1.00 after giving effect to such borrowings. The New Revolver and the New Term Loan A initially bears interest at LIBOR plus an interest rate margin of 1.75% which is subject to adjustment depending upon the Company's leverage ratio and can range from 1.50% to 2.00%. The New Term Loan A requires annual principal payments beginning on September 30, 2014 of \$25,000 in 2014, \$50,000 in 2015, \$62,500 in 2016, \$87,500 in 2017 and \$100,000 in 2018 with the balance of \$675,000 due in 2019. The New Term Loan B bears interest at LIBOR (Floor of 0.75%) plus an interest rate margin of 2.75%. The New Term Loan B requires annual principal payments of \$17,500 in 2014 and \$35,000 for each year from 2015 through 2020, with the balance of \$3,272,500 due in 2021. These New Loans under the New Credit Agreement are guaranteed by certain of the Company's direct and indirect wholly-owned domestic subsidiaries holding most of the Company's domestic assets and are secured by substantially all of the Company's and the guarantors' assets. The New Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on the amount of investments, acquisitions, the payment of dividends and redemptions and the incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company's leverage ratio is below 3.50 to 1.00. In addition, the New Credit Agreement places limitations on the amount of tangible net assets of the non-guarantor subsidiaries and also requires compliance with a maximum leverage ratio covenant.

In addition, in June 2014, the Company issued \$1,750,000 5 1/8% Senior Notes due 2024 (the 5 1/8% Senior Notes). The 5 1/8% Senior Notes pay interest on January 15 and July 15 of each year beginning January 15, 2015. The 5 1/8% Senior Notes are unsecured obligations and will rank equally in right of payment with our existing and future unsecured senior indebtedness. The 5 1/8% Senior Notes are guaranteed by each of the Company's domestic subsidiaries that guarantees the Company's New Credit Agreement. The Company may redeem up to 35% of the 5 1/8% Senior Notes at any time prior to July 15, 2017 at a certain specified price from the proceeds of one or more equity offerings. In addition, the Company may redeem the 5 1/8% Senior Notes at any time prior to July 15, 2019 at make whole redemption prices and after such date at certain specified redemption prices.

The Company received total proceeds from these borrowings of \$6,250,000, \$4,500,000 from the issuance of the New Term Loans and \$1,750,000 from the issuance of the 5 1/8% Senior Notes. The Company used a portion of the proceeds to pay off the total outstanding principal balances under its then existing Senior Secured Credit Facilities plus accrued interest totaling \$5,362,428 and in addition, to purchase pursuant to a cash tender offer \$483,093 of the outstanding principal balances of the Company's \$775,000 6 3/8% Senior Notes due 2018 (6 3/8% Senior Notes) plus

accrued interest and cash tender premium totaling \$512,386. The total amount paid for the 6 ³/₈% Senior Notes from the cash tender offer was \$1,051.25 per 1,000 of principal amount of the 6 ³/₈% Senior Notes, which resulted in the Company paying a cash tender premium of \$24,759 for the redemption of this portion of the 6 ³/₈% Senior Notes. The Company also incurred an additional \$81,569 in fees, discounts and other professional expenses associated with these transactions.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

In July 2014, the Company also purchased an additional \$188 principal amount of the 6 ³/₈% Senior Notes plus accrued interest totaling \$194 pursuant to the cash tender offer at a price of \$1,021.25 per 1,000 of principal amount of the 6 ³/₈% Senior Notes, which resulted in the Company paying an additional cash tender premium of \$4.

In addition, in July 2014, the Company redeemed the remaining outstanding principal balance of the 6 ³/₈% Senior Notes of \$291,719 at a redemption price of \$1,047.81 per 1,000 of principal amount of the 6 ³/₈% Senior Notes plus accrued interest and a redemption premium which totaled \$309,954. This resulted in an additional redemption premium of \$13,947 being recorded as debt refinancing charges.

As a result of these transactions, the Company recorded debt refinancing charges of \$97,548 that consist of the cash tender premiums, the redemption premium, the write-off of existing deferred financing costs, the write-off of certain new refinancing costs, other professional fees and losses associated with the termination of several of the Company's interest rate swap agreements.

In addition, as a result of these transactions, the Company terminated \$1,137,500 notional amounts of amortizing swaps and also terminated \$600,000 of forward swaps during June 2014, that resulted in the Company recognizing a loss of \$3,140, of which \$2,972 was previously recorded in other comprehensive income due to the Company's previously outstanding principal debt being paid-off as described above, and as a result of future forecasted transactions that are no longer probable. The loss is included as a component of the Company's debt refinancing charges. During the six months ended June 30, 2014, the Company recognized debt expense of \$6,137 from these swaps.

The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company's interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as the hedged forecasted cash flows occur, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, the Company has entered into several interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's floating rate debt, as described below. Certain cap agreements are also designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. Certain other cap agreements are ineffective cash flow hedges, and as a result, changes in the fair value of these cap agreements are reported in net income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The swap and cap agreements do not contain credit-risk contingent features.

As of June 30, 2014, the Company maintains several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts of these swap agreements totaling \$878,750. These agreements have the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's New Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the New Term Loan A margin of 1.75%. The overall weighted average effective interest rate also includes the effects of \$121,250 of unhedged New Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 1.75%. The swap agreements expire on

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

September 30, 2016 and require monthly interest payments. During the six months ended June 30, 2014, the Company recognized debt expense of \$1,592 from these swaps. As of June 30, 2014, the total fair value of these swap agreements was a net asset of approximately \$849. The Company estimates that approximately \$2,696 of existing unrealized pre-tax losses in other comprehensive income at June 30, 2014 will be reclassified into income over the next twelve months.

As of June 30, 2014, the Company maintains several interest rate cap agreements that were entered into in March 2013 with notional amounts totaling \$2,735,000 on the Company's New Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 2.50% on an equivalent amount of the Company's New Term Loan B. During the six months ended June 30, 2014, the Company recognized debt expense of \$1,220 from these caps. The cap agreements expire on September 30, 2016. As of June 30, 2014, the total fair value of these cap agreements was an asset of approximately \$2,692. During the six months ended June 30, 2014, the Company recorded a loss of \$4,874 in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

As of June 30, 2014, the Company also maintains five other interest rate cap agreements with notional amounts totaling \$1,250,000. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our New Term Loan B debt. However, as a result of the interest rate cap agreements that were entered into in March 2013, as described above, these interest rate cap agreements became ineffective cash flow hedges and as a result any changes in the fair value associated with these interest rate cap agreements will be charged to income. During the six months ended June 30, 2014, the Company recognized debt expense of \$1,794 from these caps. The cap agreements expire on September 30, 2014.

The following table summarizes the Company's derivative instruments as of June 30, 2014 and December 31, 2013:

Derivatives designated as hedging instruments	June 30, 2014		December 31, 2013	
	Balance sheet location	Fair value	Balance sheet location	Fair value
Interest rate swap agreements	Other short-term liabilities	\$ 2,696	Other short-term liabilities	\$ 12,069
Interest rate swap agreements	Other long-term assets	\$ 3,545	Other long-term assets	\$ 10,004
Interest rate cap agreements	Other long-term assets	\$ 2,692	Other long-term assets	\$ 7,567

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

The following table summarizes the effects of the Company's interest rate swap and cap agreements for the three and six months ended June 30, 2014 and 2013:

	Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements				Location of losses reclassified from accumulated OCI into income	Amount of losses reclassified from accumulated OCI into income			
	Three months ended June 30,		Six months ended June 30,			Three months ended June 30,		Six months ended June 30,	
Derivatives designated as cash flow hedges	2014	2013	2014	2013		2014	2013	2014	2013
Interest rate swap agreements	\$ (5,022)	\$ 13,266	\$ (7,786)	\$ 12,302	Debt expense (including refinancing charges)	\$ (6,694)	\$ (4,159)	\$ (10,700)	\$ (7,366)
Interest rate cap agreements	(3,527)	5,858	(4,874)	2,945	Debt expense (including refinancing charges)	(1,507)	(1,507)	(3,014)	(2,404)
Tax benefit (expense)	3,340	(7,439)	4,946	(5,931)		3,204	2,204	5,358	3,801
Total	\$ (5,209)	\$ 11,685	\$ (7,714)	\$ 9,316		\$ (4,997)	\$ (3,462)	\$ (8,356)	\$ (5,969)

As of June 30, 2014, the interest rate on the Company's New Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date and the New Term Loan B is also subject to interest rate caps if LIBOR should rise above 2.50%. See above for further details. Interest rates on the Company's senior notes are fixed by their terms. The LIBOR variable component of the Company's interest rate on a majority of the Company's New Term Loan A is economically fixed as a result of interest rate swaps.

As a result of embedded LIBOR floors on the New Term Loan B debt agreement and the swap and cap agreements, the Company's overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.51%, based upon the current margins in effect of 1.75% for the New Term Loan A and 2.75% for the New Term Loan B, as of June 30, 2014.

The Company's overall weighted average effective interest rate during the second quarter of 2014 was 4.85% and as of June 30, 2014 was 4.56%.

As of June 30, 2014, the Company had undrawn revolving credit facilities totaling \$1,000,000 of which approximately \$83,000 was committed for outstanding letters of credit. In addition, HCP has an outstanding letter of credit of approximately \$1,000 that is secured by a certificate of deposit.

9. Contingencies

The majority of the Company's revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient's medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company's revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Inquiries by the Federal Government and Certain Related Civil Proceedings

Vainer Private Civil Suit: In December 2008, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company has been in contact with the U.S. Attorney's Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC since November 2008 relating to this matter, and has been advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the *qui tam* provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney's Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators' allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company's drug administration practices for the Company's dialysis operations for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2010 U.S. Attorney Physician Relationship Investigation: In May 2010, the Company received a subpoena from the OIG's office in Dallas, Texas. The civil subpoena covers the period from January 2005 to May 2010, and seeks production of a wide range of documents relating to the Company's dialysis operations, including documents related to, among other things, financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. The Company has been advised by the attorneys conducting this civil investigation that they believe that some or all of the Company's joint ventures do not comply with the anti-kickback statute and the False Claims Act. The Company disagrees that its joint venture structure generally, which the Company believes is widely used in the dialysis industry and other segments of the healthcare industry substantially in the form that the Company uses it, violates the federal anti-kickback statute or the False Claims Act. As to individual transactions, the Company made significant effort to ensure that its joint venture structures and process complied with the rules, but the Company is talking with the government about addressing its concerns. The focus of this investigation overlaps substantially with the 2011 U.S. Attorney Physician Relationship Investigation described below. The Company has agreed to a framework for a global resolution with the United States Attorney's Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation of specific terms. The settlement will include the payment of approximately \$389,000, entry into a corporate integrity agreement, the appointment of an independent compliance monitor, and the imposition of certain other business restrictions related to a subset of the Company's joint

venture arrangements. Under the terms of the framework for resolution, the Company has agreed to unwind a limited subset of joint ventures that were created through partial divestiture to nephrologists, and agreed not to enter into this type of partial divestiture joint venture with nephrologists in the future. In 2013, the Company accrued an estimated loss contingency reserve of \$397,000 related to this matter. The final settlement remains subject to negotiation of specific terms and will continue to require management's attention and significant legal expense. The Company can make no assurances as to the final outcome.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

2011 U.S. Attorney Physician Relationship Investigation: In August 2011, the Company announced it had learned that the U.S. Attorney's Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation relates to the Company's relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlaps substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. As noted above, the Company has agreed to a framework for a global resolution with the United States Attorney's Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation of specific terms and will continue to require management's attention and significant legal expense. The Company can make no assurances as to the final outcome.

2011 U.S. Attorney Medicaid Investigation: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company's announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney's Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company's understanding that this inquiry is civil in nature. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, we reached an agreement in principle to resolve this matter. The specific terms of a settlement remain subject to ongoing negotiation.

Swoben Private Civil Suit: In April 2013, the Company's HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the *qui tam* provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a *qui tam* action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6)

and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP's motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court's disposition of the appeal is pending.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Except for the private civil complaints filed by the relators as described above, to the Company's knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management's attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators' claims (except as described above), or the potential range of damages, if any.

In re DaVita HealthCare Partners Inc. Derivative Litigation: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that our directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.

Other

The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.

A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other

California Labor Code requirements. In September 2011, the court denied the plaintiffs' motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court's decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company's consolidated financial statements. The Company intends to continue to vigorously defend against the remaining claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company's consolidated financial statements.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

10. Noncontrolling interests subject to put provisions and other commitments

The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interest may ultimately be settled, which could vary significantly from the Company's current estimates. The estimated fair values of noncontrolling interest subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial.

Additionally, the Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics or medical practices that the Company operates under management and administrative service agreements of approximately \$2,000.

Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

11. Long-term incentive compensation

Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to the dialysis and related lab services business, the HCP business, corporate support costs, and the ancillary services and strategic initiatives.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

The Company's stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.

During the six months ended June 30, 2014, the Company granted 1,248 stock-settled stock appreciation rights with an aggregate grant-date fair value of \$19,997 and a weighted-average expected life of approximately 4.2 years, and also granted 316 stock units with an aggregate grant-date fair value of \$22,809 and a weighted-average expected life of approximately 3.4 years.

For the six months ended June 30, 2014 and 2013, the Company recognized \$52,960 and \$38,773, respectively, in total LTIP expense, of which \$29,699 and \$32,266, respectively, was stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation through June 30, 2014 and 2013 was \$10,997 and \$12,171, respectively. As of June 30, 2014, there was \$162,351 of total estimated unrecognized compensation cost for outstanding LTIP awards, including \$99,331 related to stock-based compensation arrangements under the Company's equity compensation and stock purchase plans. The Company expects to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.1 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.4 years.

For the six months ended June 30, 2014 and 2013, the Company received \$42,110 and \$36,524, respectively, in actual tax benefits upon the exercise of stock awards.

12. Comprehensive income

	For the three months ended June 30, 2014				For the six months ended June 30, 2014			
Interest rate swap and cap agreements	Investment securities	Foreign translation adjustments	Accumulated other comprehensive income (loss)	Interest rate swap and cap agreements	Investment securities	Foreign translation adjustments	Accumulated other comprehensive income (loss)	
Beginning balance	\$ (1,490)	\$ 3,244	\$ (3,393)	\$ (1,639)	\$ (2,344)	\$ 3,120	\$ (3,421)	\$ (2,645)
	(8,549)	875	1,939	(5,736)	(12,660)	1,405	1,967	(9,289)

Unrealized (losses) gains								
Related income tax benefit (expense)	3,340	(297)		3,044	4,946	(496)		4,451
	(5,209)	578	1,939	(2,692)	(7,714)	909	1,967	(4,838)
Reclassification from accumulated other comprehensive income into net income	8,201			8,201	13,714	(340)		13,374
Related tax	(3,204)			(3,204)	(5,358)	133		(5,225)
	4,997			4,997	8,356	(207)		8,149
Ending balance	\$ (1,702)	\$ 3,822	\$ (1,454)	\$ 666	\$ (1,702)	\$ 3,822	\$ (1,454)	\$ 666

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

	For the three months ended June 30, 2013				For the six months ended June 30, 2013			
	Interest rate swap and cap agreements	Investment securities	Foreign currency translation adjustments	Accumulated other comprehensive income (loss)	Interest rate swap and cap agreements	Investment securities	Foreign currency translation adjustments	Accumulated other comprehensive income (loss)
Beginning balance	\$ (15,264)	\$ 1,834	\$ (3,311)	\$ (16,741)	\$ (15,402)	\$ 1,310	\$ (1,205)	\$ (15,297)
Unrealized gains (losses)	19,124	166	(1,841)	17,449	15,247	1,178	(3,947)	12,478
Related income tax (expense) benefit	(7,439)	(65)		(7,504)	(5,931)	(459)		(6,390)
	11,685	101	(1,841)	9,945	9,316	719	(3,947)	6,088
Reclassification from accumulated other comprehensive income into net income	5,666			5,666	9,770	(155)		9,615
Related tax	(2,204)			(2,204)	(3,801)	61		(3,740)
	3,462			3,462	5,969	(94)		5,875
Ending balance	\$ (117)	\$ 1,935	\$ (5,152)	\$ (3,334)	\$ (117)	\$ 1,935	\$ (5,152)	\$ (3,334)

The reclassification of net swap and cap realized losses into income are recorded as debt expense in the corresponding condensed consolidated statements of income. See Note 8 to the condensed consolidated financial statements for further details.

The reclassification of net investment realized gains into income are recorded in other income in the corresponding condensed consolidated statements of income. See Note 4 to the condensed consolidated financial statements for further details.

13. Acquisitions

During the first six months of 2014, the Company acquired dialysis businesses and other businesses consisting of one dialysis center located in the U.S., three dialysis centers located outside the U.S. and other medical businesses for a total of \$98,442 in net cash and deferred purchase price obligations totaling \$14,156. The assets and liabilities for all acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company's condensed consolidated financial statements and operating results from the designated effective dates of the acquisitions. Certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of medical claims reserves and certain other working capital items relating to several of these acquisitions are pending final quantification.

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values:

	Six months ended June 30, 2014
Tangible assets, principally leasehold improvements and equipment, net of cash	\$ 858
Amortizable intangible and other long-term assets	69,366
Goodwill	42,374
Aggregate purchase price	\$ 112,598

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

Amortizable intangible assets acquired during the first six months of 2014 had weighted-average estimated useful lives of 9.9 years. The total amount of goodwill deductible for tax purposes associated with these acquisitions was approximately \$27,789.

Contingent earn-out obligations

The Company has several contingent earn-out obligations associated with acquisitions that could result in the Company paying the former shareholders of those acquired companies a total of up to \$136,300 or a portion of that amount if certain EBITDA performance targets and quality margins are met over the next two years, if certain percentages of operating income are met over the next three years or if certain percentages of other annual EBITDA targets are met. As of June 30, 2014, the Company has estimated the fair value of these contingent earn-out obligations to be \$38,335.

Contingent earn-out obligations will be remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the re-measurement recorded in earnings. See Note 15 to the condensed consolidated financial statements for further details. Of the total contingent earn-out obligations of \$38,335 recognized at June 30, 2014, a total of \$13,682 is included in other liabilities and the remaining \$24,653 is included in other long-term liabilities in the Company's condensed consolidated balance sheet.

The following is a reconciliation of changes in the contingent earn-out obligations for the six months ended June 30, 2014:

Beginning balance, January 1, 2014	\$ 28,058
Contingent earn-out obligations associated with acquisitions	13,772
Remeasurement of fair value for other contingent earn-outs	(1,969)
Payments of contingent earn-outs	(1,526)
	\$ 38,335

14. Variable interest entities

The Company relies on the operating activities of certain entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs).

Under U.S. generally accepted accounting principles (GAAP), VIEs typically include (i) those for which the entity's equity is not sufficient to finance its activities without additional subordinated financial support; (ii) those for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity's economic performance, the obligation to absorb the entity's expected losses, or the right to receive the entity's expected returns; or (iii) those for which the voting rights of some investors are not proportional to their obligations to absorb the entity's losses.

Under U.S. GAAP, the Company has determined that substantially all of the entities it is associated with that qualify as VIEs must be included in its consolidated financial statements. The Company manages these entities and provides operating and capital funding as necessary for the entities to accomplish their operational and strategic objectives. A number of these entities are subject to nominee share ownership or share transfer

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. In other cases the Company's management agreements with these entities include both financial terms and protective and participating rights to the entities' operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for the entities to the Company. In some cases such entities are subject to broad exclusivity or noncompetition restrictions that benefit the Company. Further, in some cases the Company has contractual arrangements with its related party nominee owners that effectively indemnify these parties from the economic losses from, or entitle the Company to the economic benefits of, these entities.

The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations. At June 30, 2014, these condensed consolidated financial statements include total assets of VIEs of \$515,618 and total liabilities and noncontrolling interests of VIEs to third parties of \$307,133.

The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. See Note 4 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

15. Fair value of financial instruments

The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by the FASB.

The following table summarizes the Company's assets, liabilities and temporary equity measured at fair value on a recurring basis as of June 30, 2014:

	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Total			

Assets				
Available-for-sale securities	\$ 25,685	\$ 25,685	\$	\$
Interest rate cap agreements	\$ 2,692	\$	\$ 2,692	\$
Interest rate swap agreements	\$ 3,545	\$	\$ 3,545	\$
Funds on deposit with third parties	\$ 72,575	\$ 72,575	\$	\$
Liabilities				
Contingent earn-out obligations	\$ 38,335	\$	\$	\$ 38,335
Interest rate swap agreements	\$ 2,696	\$	\$ 2,696	\$
Temporary equity				
Noncontrolling interests subject to put provisions	\$ 760,242	\$	\$	\$ 760,242

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

The available for sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at fair value based upon quoted prices reported by each mutual fund. See Note 4 to these condensed consolidated financial statements for further discussion.

The interest rate swap and cap agreements are recorded at fair value based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate swap and cap agreements would be materially different from the fair values currently reported. See Note 8 to the condensed consolidated financial statements for further discussion.

The funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices.

The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs including projected EBITDA, estimated probabilities of achieving gross margin of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair values of the quality results amounts. The estimated fair value of these contingent earn-out obligations will be remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value.

See Note 10 to these condensed consolidated financial statements for a discussion of the Company's methodology for estimating the fair value of noncontrolling interests subject to put obligations.

Other financial instruments consist primarily of cash, accounts receivable, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at June 30, 2014 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company's Senior Secured Credit Facilities totaled \$4,482,500 as of June 30, 2014, and the fair value was approximately \$4,526,300 based upon quoted market prices. The fair value of the Company's senior notes was approximately \$4,229,200 at June 30, 2014 based upon quoted market prices, as compared to the carrying amount of \$4,066,907.

16. Segment reporting

The Company operates two major divisions, Kidney Care and HCP. The Kidney Care division is comprised of the Company's U.S. dialysis and related lab services business and various other ancillary services and strategic initiatives, including its international dialysis operations. The HCP division is comprised of the Company's HealthCare Partners integrated healthcare business.

As of June 30, 2014, the Company's ancillary services and strategic initiatives consisted primarily of pharmacy services, disease management services, vascular access services, ESRD clinical research programs, physician services, direct primary care and the Company's international dialysis operations.

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

The Company's operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company's chief operating decision maker in making decisions about allocating resources to and assessing the financial results of the Company's different business units. The chief operating decision maker for the Company is its Chief Executive Officer.

The Company's separate operating segments include its U.S. dialysis and related lab services business, its HCP operations in each region, each of its ancillary services and strategic initiatives, and its international operations in the European and Middle Eastern, Asia Pacific, and Latin American regions. The U.S. dialysis and related lab services business and the HCP business each qualify as separately reportable segments, and all of the other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category.

The Company's operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial results of the operating segments. For internal management reporting, segment operations include direct segment operating expenses but exclude corporate support expenses, which consist primarily of indirect labor, benefits and long-term incentive based compensation of certain departments which provide support to all of the Company's different operating lines of business. Corporate support expenses in the second quarter of 2014 have been reduced by internal management fees paid by the Company's ancillary lines of businesses.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

	Three months ended June 30,		Six months ended June 30,	
	2014	2013	2014	2013
Segment net revenues:				
U.S. dialysis and related lab services				
Patient service revenues:				
External sources	\$ 2,096,605	\$ 1,980,267	\$ 4,125,349	\$ 3,889,050
Intersegment revenues	9,084	8,158	16,916	15,669
Total dialysis and related lab services revenues	2,105,689	1,988,425	4,142,265	3,904,719
Less: Provision for uncollectible accounts	(84,227)	(69,585)	(165,690)	(136,656)
Net dialysis and related lab services patient service revenues	2,021,462	1,918,840	3,976,575	3,768,063
Other revenues ⁽¹⁾	3,579	3,424	6,732	6,319
Total net dialysis and related lab services revenues	2,025,041	1,922,264	3,983,307	3,774,382
HCP				
HCP revenues:				
Capitated revenues	783,182	692,357	1,554,724	1,438,428
Net patient service revenues	58,076	49,433	114,297	103,035
Other revenues ⁽²⁾	46,029	19,216	58,553	23,302
Intersegment capitated and other revenues	204		357	
Total revenues	887,491	761,006	1,727,931	1,564,765
Other Ancillary services and strategic initiatives				
Net patient service revenues U.S.	4,709	3,050	8,862	6,490
Net patient service revenues International	24,035	13,294	47,281	24,357
Capitated revenues	16,187	17,717	32,210	34,261
Other external sources U.S.	222,716	160,988	429,671	309,745
Other external sources International	1,598	1,512	3,276	2,924

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Intersegment revenues	4,474	3,397	9,293	6,176
Total ancillary services and strategic initiatives revenues	273,719	199,958	530,593	383,953
Total net segment revenues	3,186,251	2,883,228	6,241,831	5,723,100
Elimination of intersegment revenues	(13,762)	(11,555)	(26,566)	(21,845)
Consolidated net revenues	\$ 3,172,489	\$ 2,871,673	\$ 6,215,265	\$ 5,701,255
Segment operating margin (loss):				
U.S. dialysis and related lab services	\$ 407,948	\$ 401,415	\$ 794,648	\$ 486,228
HCP	82,048	81,382	136,002	189,466
Other Ancillary services and strategic initiatives	(1,920)	(6,791)	(243)	(21,392)
Total segment margin	488,076	476,006	930,407	654,302
Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:				
Contingent earn-out obligation adjustment		56,977		56,977
Corporate support expenses	(3,781)	(10,963)	(4,887)	(22,398)
Consolidated operating income	484,295	522,020	925,520	688,881
Debt expense	(106,132)	(108,096)	(212,467)	(213,913)
Debt refinancing charges	(97,548)		(97,548)	
Other income (loss)	1,693	(1,374)	3,391	(776)
Consolidated income from continuing operations before income taxes	\$ 282,308	\$ 412,550	\$ 618,896	\$ 474,192

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

- (1) Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.
- (2) Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.

For the three months ended June 30, 2014, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was \$99,163, \$42,260 and \$4,484, respectively.

For the six months ended June 30, 2014, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was \$195,606, \$83,997 and \$8,883, respectively.

For the three months ended June 30, 2013, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was \$88,588, \$38,590 and \$3,411, respectively.

For the six months ended June 30, 2013, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was \$173,540, \$76,607 and \$6,351, respectively.

Summary of assets by segment is as follows:

	June 30, 2014	December 31, 2013
Segment assets		
U.S. dialysis and related lab services	\$ 10,876,860	\$ 10,248,993
HCP	6,369,644	6,265,767
Other Ancillary services and strategic initiatives	679,067	584,117
Consolidated assets	\$ 17,925,571	\$ 17,098,877

For the three and six months ended June 30, 2014, the total amount of expenditures for property and equipment, excluding capital leases was \$136,660 and \$249,869, respectively, for the U.S. dialysis and related lab services, was \$5,777 and \$10,279, respectively, for HCP and was \$9,594 and \$18,445, respectively, for the ancillary services and strategic initiatives.

For the three and six months ended June 30, 2013, the total amount of expenditures for property and equipment, excluding capital leases was \$128,699 and \$230,775, respectively, for the U.S. dialysis and related lab services, and was \$7,840 and \$14,379, respectively, for HCP and was \$5,133 and \$13,242, respectively, for the ancillary services and strategic initiatives.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

17. Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries

The effects of changes in DaVita HealthCare Partners Inc.'s ownership interest on the Company's equity are as follows:

	Three months ended		Six months ended	
	June 30,		June 30,	
	2014	2013	2014	2013
Net income attributable to DaVita HealthCare Partners Inc.	\$ 147,683	\$ 254,376	\$ 330,972	\$ 284,540
(Decrease) increase in paid-in capital for sales of noncontrolling interests	(66)	(78)	15	(887)
Increase (decrease) in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest	1,247	(474)	1,457	(474)
Net transfers to noncontrolling interests	1,181	(552)	1,472	(1,361)
Change from net income attributable to DaVita HealthCare Partners Inc. and transfers to noncontrolling interests	\$ 148,864	\$ 253,824	\$ 332,444	\$ 283,179

18. New accounting standards

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers*, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In April 2014, the FASB issued ASU No. 2014-08, *Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity*. The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a

strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization's operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization's results from continuing operations. The amendments in this ASU enhance convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). Part of the new definition of discontinued operation is based on elements of the definition of discontinued operations in IFRS 5, *Non-Current Assets Held for Sale and Discontinued Operations*. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company's condensed consolidated financial statements.

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

19. Condensed consolidating financial statements

The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company's consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other administrative services. The Company's senior notes are guaranteed by substantially all of its domestic wholly-owned subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, including by merger or consolidation or the sale of all equity interests in such subsidiary owned by the Company, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Non-wholly-owned subsidiaries, certain wholly-owned subsidiaries, foreign subsidiaries, joint ventures, partnerships, non-owned entities and third parties are not guarantors of these obligations.

Condensed Consolidating Statements of Income

For the three months ended June 30, 2014	DaVita HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	Consolidated total
Patient service revenues	\$	\$ 1,517,268	\$ 668,312	\$ 1,669	\$ 2,187,249
Less: Provision for uncollectible accounts		(57,281)	(30,771)		(88,052)
Net patient service revenues		1,459,987	637,541	1,669	2,099,197
Capitated revenues		414,366	385,030	(27)	799,369
Other revenues	181,199	424,755	35,712	(367,743)	273,923
Total net revenues	181,199	2,299,108	1,058,283	(366,101)	3,172,489
Operating expenses	122,815	2,033,828	897,652	(366,101)	2,688,194
Operating income	58,384	265,280	160,631		484,295
Debt expense, including debt refinancing charges	(202,258)	(94,169)	(10,180)	102,927	(203,680)
Other income (expense)	99,532	4,166	922	(102,927)	1,693
Income tax (benefit) expense	(17,958)	111,415	7,430		100,887
Equity earnings in subsidiaries	174,067	110,205		(284,272)	

Net income	147,683	174,067	143,943	(284,272)	181,421
Less: Net income attributable to noncontrolling interests				(33,738)	(33,738)
Net income attributable to DaVita HealthCare Partners Inc.	\$ 147,683	\$ 174,067	\$ 143,943	\$ (318,010)	\$ 147,683

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

For the three months ended June 30, 2013	DaVita HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	Consolidated total
Patient service revenues	\$	\$ 1,476,135	\$ 581,208	\$ (8,692)	\$ 2,048,651
Less: Provision for uncollectible accounts		(37,218)	(34,973)		(72,191)
Net patient service revenues		1,438,917	546,235	(8,692)	1,976,460
Capitated revenues		337,312	374,451	(1,689)	710,074
Other revenues	166,650	374,577	21,183	(377,271)	185,139
Total net revenues	166,650	2,150,806	941,869	(387,652)	2,871,673
Operating expenses	71,881	1,827,141	838,283	(387,652)	2,349,653
Operating income	94,769	323,665	103,586		522,020
Debt expense	(107,337)	(95,600)	(11,247)	106,088	(108,096)
Other income (expense)	100,947	3,714	53	(106,088)	(1,374)
Income tax expense	29,458	97,729	2,005		129,192
Equity earnings in subsidiaries	195,455	61,405		(256,860)	
Net income	254,376	195,455	90,387	(256,860)	283,358
Less: Net income attributable to noncontrolling interests				(28,982)	(28,982)
Net income attributable to DaVita HealthCare Partners Inc.	\$ 254,376	\$ 195,455	\$ 90,387	\$ (285,842)	\$ 254,376

For the six months ended June 30, 2014	DaVita HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	Consolidated total
Patient service revenues	\$	\$ 3,030,545	\$ 1,267,669	\$ 3,133	\$ 4,301,347
Less: Provision for uncollectible accounts		(107,160)	(64,089)		(171,249)
Net patient service revenues		2,923,385	1,203,580	3,133	4,130,098
Capitated revenues		818,913	768,428	(407)	1,586,934
Other revenues	344,242	818,310	68,003	(732,322)	498,233

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Total net revenues	344,242	4,560,608	2,040,011	(729,596)	6,215,265
Operating expenses	235,112	4,014,282	1,769,947	(729,596)	5,289,745
Operating income	109,130	546,326	270,064		925,520
Debt expense, including debt refinancing charges	(307,541)	(188,806)	(19,932)	206,264	(310,015)
Other income (expense)	199,475	8,935	1,245	(206,264)	3,391
Income tax expense	431	215,546	9,761		225,738
Equity earnings in subsidiaries	330,339	179,430		(509,769)	
Net income	330,972	330,339	241,616	(509,769)	393,158
Less: Net income attributable to noncontrolling interests				(62,186)	(62,186)
Net income attributable to DaVita HealthCare Partners Inc.	\$ 330,972	\$ 330,339	\$ 241,616	\$ (571,955)	\$ 330,972

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

For the six months ended June 30, 2013	DaVita				Consolidated total
	HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	
Patient service revenues	\$	\$ 2,928,355	\$ 1,117,866	\$ (17,697)	\$ 4,028,524
Less: Provision for uncollectible accounts		(101,075)	(41,173)		(142,248)
Net patient service revenues		2,827,280	1,076,693	(17,697)	3,886,276
Capitated revenues		697,336	778,126	(2,773)	1,472,689
Other revenues	302,025	733,034	38,840	(731,609)	342,290
Total net revenues	302,025	4,257,650	1,893,659	(752,079)	5,701,255
Operating expenses	192,385	3,908,364	1,663,704	(752,079)	5,012,374
Operating income	109,640	349,286	229,955		688,881
Debt expense	(212,668)	(190,315)	(21,970)	211,040	(213,913)
Other income (expense)	201,168	9,681	(585)	(211,040)	(776)
Income tax expense	34,055	94,517	15,764		144,336
Equity earnings in subsidiaries	220,455	127,482		(347,937)	
Income from continuing operations	284,540	201,617	191,636	(347,937)	329,856
Discontinued operations			13,236		13,236
Net income	284,540	201,617	204,872	(347,937)	343,092
Less: Net income attributable to noncontrolling interests				(58,552)	(58,552)
Net income attributable to DaVita HealthCare Partners Inc.	\$ 284,540	\$ 201,617	\$ 204,872	\$ (406,489)	\$ 284,540

Condensed Consolidating Statements of Comprehensive Income

For the three months ended June 30, 2014	DaVita				Consolidated total
	HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	
Net income	\$ 147,683	\$ 174,067	\$ 143,943	\$ (284,272)	\$ 181,421
Other comprehensive income	2,305				2,305

Total comprehensive income	149,988	174,067	143,943	(284,272)	183,726
Less: comprehensive income attributable to the noncontrolling interests				(33,738)	(33,738)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 149,988	\$ 174,067	\$ 143,943	\$ (318,010)	\$ 149,988

For the three months ended June 30, 2013

Net income	\$ 254,376	\$ 195,455	\$ 90,387	\$ (256,860)	\$ 283,358
Other comprehensive income	13,407				13,407
Total comprehensive income	267,783	195,455	90,387	(256,860)	296,765
Less: comprehensive income attributable to the noncontrolling interests				(28,982)	(28,982)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 267,783	\$ 195,455	\$ 90,387	\$ (285,842)	\$ 267,783

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

For the six months ended June 30, 2014	DaVita				Consolidated
	HealthCare	Guarantor	Non-Guarantor	Consolidating	Consolidated
	Partners Inc.	subsidiaries	subsidiaries	adjustments	total
Net income	\$ 330,972	\$ 330,339	\$ 241,616	\$ (509,769)	\$ 393,158
Other comprehensive income	3,311				3,311
Total comprehensive income	334,283	330,339	241,616	(509,769)	396,469
Less: comprehensive income attributable to the noncontrolling interests				(62,186)	(62,186)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 334,283	\$ 330,339	\$ 241,616	\$ (571,955)	\$ 334,283
For the six months ended June 30, 2013					
Net income	\$ 284,540	\$ 201,617	\$ 204,872	\$ (347,937)	\$ 343,092
Other comprehensive income	11,963				11,963
Total comprehensive income	296,503	201,617	204,872	(347,937)	355,055
Less: comprehensive income attributable to the noncontrolling interests				(58,552)	(58,552)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 296,503	\$ 201,617	\$ 204,872	\$ (406,489)	\$ 296,503

Condensed Consolidating Balance Sheets

As of June 30, 2014	DaVita				Consolidated
	HealthCare	Guarantor	Non-Guarantor	Consolidating	Consolidated
	Partners Inc.	subsidiaries	subsidiaries	adjustments	total
Cash and cash equivalents	\$ 1,081,021	\$ 137,229	\$ 202,723	\$	\$ 1,420,973
Accounts receivable, net		953,474	596,778		1,550,252
Other current assets	83,242	971,776	135,004		1,190,022
Total current assets	1,164,263	2,062,479	934,505		4,161,247
Property and equipment, net	187,939	1,394,182	708,723		2,290,844

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Amortizable intangibles, net	92,421	1,867,978	62,476		2,022,875
Investments in subsidiaries	8,784,145	1,589,418		(10,373,563)	
Intercompany receivables	3,645,401		545,592	(4,190,993)	
Other long-term assets and investments	59,487	62,812	74,263		196,562
Goodwill		7,875,336	1,378,707		9,254,043
Total assets	\$ 13,933,656	\$ 14,852,205	\$ 3,704,266	\$ (14,564,556)	\$ 17,925,571
Current liabilities	496,066	1,744,652	367,430		2,608,148
Intercompany payables		3,115,717	1,075,276	(4,190,993)	
Long-term debt and other long-term liabilities	8,157,874	1,207,691	234,791		9,600,356
Noncontrolling interests subject to put provisions	493,945			266,297	760,242
Total DaVita HealthCare Partners Inc. shareholders equity	4,785,771	8,784,145	1,589,418	(10,373,563)	4,785,771
Noncontrolling interests not subject to put provisions			437,351	(266,297)	171,054
Total equity	4,785,771	8,784,145	2,026,769	(10,639,860)	4,956,825
Total liabilities and equity	\$ 13,933,656	\$ 14,852,205	\$ 3,704,266	\$ (14,564,556)	\$ 17,925,571

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

As of December 31, 2013	DaVita HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	Consolidated total
Cash and cash equivalents	\$ 602,188	\$ 175,004	\$ 169,057	\$	\$ 946,249
Accounts receivable, net		939,543	545,620		1,485,163
Other current assets	27,910	908,010	104,946		1,040,866
Total current assets	630,098	2,022,557	819,623		3,472,278
Property and equipment, net	177,633	1,377,924	633,854		2,189,411
Amortizable intangibles, net	77,531	1,882,685	64,157		2,024,373
Investments in subsidiaries	8,231,059	1,389,558		(9,620,617)	
Intercompany receivables	3,983,214		480,993	(4,464,207)	
Other long-term assets and investments	61,391	67,402	71,048		199,841
Goodwill		7,837,421	1,375,553		9,212,974
Total assets	\$ 13,160,926	\$ 14,577,547	\$ 3,445,228	\$ (14,084,824)	\$ 17,098,877
Current liabilities	\$ 328,875	\$ 1,774,634	\$ 358,540	\$	\$ 2,462,049
Intercompany payables		3,421,198	1,043,009	(4,464,207)	
Long-term debt and other long-term liabilities	7,948,390	1,150,656	234,941		9,333,987
Noncontrolling interests subject to put provisions	451,182			246,118	697,300
Total DaVita HealthCare Partners Inc. shareholders equity	4,432,479	8,231,059	1,389,558	(9,620,617)	4,432,479
Noncontrolling interests not subject to put provisions			419,180	(246,118)	173,062
Total equity	4,432,479	8,231,059	1,808,738	(9,866,735)	4,605,541
Total liabilities and equity	\$ 13,160,926	\$ 14,577,547	\$ 3,445,228	\$ (14,084,824)	\$ 17,098,877

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Condensed Consolidating Statements of Cash Flows

For the six months ended June 30, 2014	DaVita HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	Consolidated total
Cash flows from operating activities:					
Net income	\$ 330,972	\$ 330,339	\$ 241,616	\$ (509,769)	\$ 393,158
Changes in operating assets and liabilities and non-cash items included in net income	(191,299)	7,007	(37,137)	509,769	288,340
Net cash provided by operating activities	139,673	337,346	204,479		681,498
Cash flows from investing activities:					
Additions of property and equipment, net	(25,377)	(123,519)	(129,697)		(278,593)
Acquisitions		(97,057)	(1,385)		(98,442)
Proceeds from asset and business sales		215			215
Purchases/proceeds from investment sales and other items	(58,496)	(5,263)	(2,276)		(66,035)
Net cash used in investing activities	(83,873)	(225,624)	(133,358)		(442,855)
Cash flows from financing activities:					
Long-term debt and related financing costs, net	353,406	(7,158)	2,188		348,436
Intercompany borrowing	139,052	(137,529)	(1,523)		
Other items	(69,425)	(4,810)	(37,553)		(111,788)
Net cash provided by (used in) financing activities	423,033	(149,497)	(36,888)		236,648
Effect of exchange rate changes on cash			(567)		(567)
Net increase (decrease) in cash and cash equivalents	478,833	(37,775)	33,666		474,724
Cash and cash equivalents at beginning of period	602,188	175,004	169,057		946,249

Cash and cash equivalents at end of period	\$ 1,081,021	\$ 137,229	\$ 202,723	\$	\$ 1,420,973
--	--------------	------------	------------	----	--------------

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

For the six months ended June 30, 2013	DaVita HealthCare Partners Inc.	Guarantor subsidiaries	Non-Guarantor subsidiaries	Consolidating adjustments	Consolidated total
Cash flows from operating activities:					
Net income	\$ 284,540	\$ 201,617	\$ 204,872	\$ (347,937)	\$ 343,092
Changes in operating assets and liabilities and non-cash items included in net income	(271,776)	288,254	(21,481)	347,937	342,934
Net cash provided by operating activities	12,764	489,871	183,391		686,026
Cash flows from investing activities:					
Additions of property and equipment, net	(24,213)	(131,671)	(102,512)		(258,396)
Acquisitions		(119,818)	(32,294)		(152,112)
Proceeds from asset sales	60,650	3,713			64,363
Purchases of investments and other items	(2,201)	359	100		(1,742)
Net cash provided by (used in) investing activities	34,236	(247,417)	(134,706)		(347,887)
Cash flows from financing activities:					
Long-term debt and related financing costs, net	(238,400)	(5,496)	(7,472)		(251,368)
Intercompany borrowing	250,330	(284,739)	34,409		
Other items	37,264	5,429	(45,074)		(2,381)
Net cash provided by (used in) financing activities	49,194	(284,806)	(18,137)		(253,749)
Effect of exchange rate changes on cash			(234)		(234)
Net increase (decrease) in cash and cash equivalents	96,194	(42,352)	30,314		84,156
Cash and cash equivalents at beginning of period	195,037	166,107	172,604		533,748
Cash and cash equivalents at end of period	\$ 291,231	\$ 123,755	\$ 202,918	\$	\$ 617,904

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

20. Supplemental data

The following information is presented as supplemental data as required by the indentures governing our senior notes.

Condensed Consolidating Statements of Income

	Consolidated	Physician	Unrestricted	Company and
For the three months ended June 30, 2014	Total	Groups	Subsidiaries	Restricted
				Subsidiaries⁽¹⁾
Patient service operating revenues	\$ 2,187,249	\$ 29,361	\$	\$ 2,157,888
Less: Provision for uncollectible accounts	(88,052)	(1,979)		(86,073)
Net patient service operating revenues	2,099,197	27,382		2,071,815
Capitated revenues	799,369	368,551		430,818
Other revenues	273,923	2,313		271,610
Total net operating revenues	3,172,489	398,246		2,774,243
Operating expenses	2,688,194	386,281	(16)	2,301,929
Operating income	484,295	11,965	16	472,314
Debt expense, including refinancing charges	(203,680)	(3,423)		(200,257)
Other income	1,693	25		1,668
Income tax expense	100,887	2,712	7	98,168
Net income	181,421	5,855	9	175,557
Minority interests	(33,738)			(33,738)
Net income attributable to DaVita HealthCare Partners Inc.	\$ 147,683	\$ 5,855	\$ 9	\$ 141,819

	Consolidated	Physician	Unrestricted	Company and
For the six months ended June 30, 2014	Total	Groups	Subsidiaries	Restricted
				Subsidiaries⁽¹⁾
Patient service operating revenues	\$ 4,301,347	\$ 60,500	\$	\$ 4,240,847

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Less: Provision for uncollectible accounts	(171,249)	(2,589)		(168,660)
Net patient service operating revenues	4,130,098	57,911		4,072,187
Capitated revenues	1,586,934	734,680		852,254
Other revenues	498,233	2,879		495,354
Total net operating revenues	6,215,265	795,470		5,419,795
Operating expenses	5,289,745	775,799	236	4,513,710
Operating income	925,520	19,671	(236)	906,085
Debt expense, including refinancing charges	(310,015)	(6,618)		(303,397)
Other income	3,391	33		3,358
Income tax expense	225,738	4,157	(94)	221,675
Net income	393,158	8,929	(142)	384,371
Minority interests	(62,186)			(62,186)
Net income attributable to DaVita HealthCare Partners Inc.	\$ 330,972	\$ 8,929	\$ (142)	\$ 322,185

(1) After the elimination of the unrestricted subsidiaries and the physician groups

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

Condensed Consolidating Statements of Comprehensive Income

	Consolidated	Physician	Unrestricted	Company and
For the three months ended June 30, 2014	Total	Groups	Subsidiaries	Restricted
				Subsidiaries⁽¹⁾
Net income	\$ 181,421	\$ 5,855	\$ 9	\$ 175,557
Other comprehensive income	2,305			2,305
Total comprehensive income	183,726	5,855	9	177,862
Less: comprehensive income attributable to the noncontrolling interests	(33,738)			(33,738)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 149,988	\$ 5,855	\$ 9	\$ 144,124

	Consolidated	Physician	Unrestricted	Company and
For the six months ended June 30, 2014	Total	Groups	Subsidiaries	Restricted
				Subsidiaries⁽¹⁾
Net income	\$ 393,158	\$ 8,929	\$ (142)	\$ 384,371
Other comprehensive income	3,311			3,311
Total comprehensive income	396,469	8,929	(142)	387,682
Less: comprehensive income attributable to the noncontrolling interests	(62,186)			(62,186)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	\$ 334,283	\$ 8,929	\$ (142)	\$ 325,496

(1) After the elimination of the unrestricted subsidiaries and the physician groups

Condensed Consolidating Balance Sheets

As of June 30, 2014	Consolidated Total	Physician Groups	Unrestricted Subsidiaries	Company and Restricted Subsidiaries⁽¹⁾
Cash and cash equivalents	\$ 1,420,973	\$ 117,313	\$	\$ 1,303,660
Accounts receivable, net	1,550,252	239,428		1,310,824
Other current assets	1,190,022	27,776		1,162,246
Total current assets	4,161,247	384,517		3,776,730
Property and equipment, net	2,290,844	5,006		2,285,838
Amortizable intangibles, net	2,022,875	6,794		2,016,081
Other long-term assets	196,562	69,311	3,089	124,162
Goodwill	9,254,043	9,181		9,244,862
Total assets	\$ 17,925,571	\$ 474,809	\$ 3,089	\$ 17,447,673
Current liabilities	\$ 2,608,148	\$ 175,238	\$	\$ 2,432,910
Payables to parent		202,448	3,089	(205,537)
Long-term debt and other long-term liabilities	9,600,356	83,106		9,517,250
Noncontrolling interests subject to put provisions	760,242			760,242
Total DaVita HealthCare Partners Inc. shareholders equity	4,785,771	14,017		4,771,754
Noncontrolling interests not subject to put provisions	171,054			171,054
Shareholders equity	4,956,825	14,017		4,942,808
Total liabilities and shareholder s equity	\$ 17,925,571	\$ 474,809	\$ 3,089	\$ 17,447,673

Table of Contents**DAVITA HEALTHCARE PARTNERS INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

(dollars and shares in thousands, except per share data)

As of December 31, 2013	Consolidated Total	Physician Groups	Unrestricted Subsidiaries	Company and Restricted Subsidiaries⁽¹⁾
Cash and cash equivalents	\$ 946,249	\$ 127,309	\$	\$ 818,940
Accounts receivable, net	1,485,163	235,463		1,249,700
Other current assets	1,040,866	35,640		1,005,226
Total current assets	3,472,278	398,412		3,073,866
Property and equipment, net	2,189,411	5,541		2,183,870
Amortizable intangibles, net	2,024,373	7,283		2,017,090
Other long-term assets	199,841	64,013	3,325	132,503
Goodwill	9,212,974	8,981		9,203,993
Total assets	\$ 17,098,877	\$ 484,230	\$ 3,325	\$ 16,611,322
Current liabilities	\$ 2,462,049	\$ 193,079	\$	\$ 2,268,970
Payables to parent		194,958	3,325	(198,283)
Long-term debt and other long-term liabilities	9,333,987	94,727		9,239,260
Noncontrolling interests subject to put provisions	697,300			697,300
Total DaVita HealthCare Partners Inc. shareholders equity	4,432,479	1,466		4,431,013
Noncontrolling interests not subject to put provisions	173,062			173,062
Shareholders equity	4,605,541	1,466		4,604,075
Total liabilities and shareholder s equity	\$ 17,098,877	\$ 484,230	\$ 3,325	\$ 16,611,322

(1) After the elimination of the unrestricted subsidiaries and the physician groups

Table of Contents

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Condensed Consolidating Statements of Cash Flows

For the six months ended June 30, 2014	Consolidated Total	Physician Groups	Unrestricted Subsidiaries	Company and Restricted Subsidiaries ⁽¹⁾
Cash flows from operating activities:				
Net income	\$ 393,158	\$ 8,929	\$ (142)	\$ 384,371
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	288,340	(27,961)	142	316,159
Net cash provided by (used in) operating activities	681,498	(19,032)		700,530
Cash flows from investing activities:				
Additions of property and equipment	(278,593)	(20)		(278,573)
Acquisitions and divestitures, net	(98,442)			(98,442)
Proceeds from discontinued operations	215			215
Investments and other items	(66,035)	(2,276)		(63,759)
Net cash used in investing activities	(442,855)	(2,296)		(440,559)
Cash flows from financing activities:				
Long-term debt	348,436			348,436
Intercompany		11,332		(11,332)
Other items	(111,788)			(111,788)
Net cash provided by financing activities	236,648	11,332		225,316
Effect of exchange rate changes on cash	(567)			(567)
Net increase (decrease) in cash	474,724	(9,996)		484,720
Cash at beginning of year	946,249	127,309		818,940
Cash at end of year	\$ 1,420,973	\$ 117,313	\$	\$ 1,303,660

⁽¹⁾ After the elimination of the unrestricted subsidiaries and the physician groups

Table of Contents**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Forward-looking statements**

This Management's Discussion and Analysis of Financial Condition and Results of Operations contains statements that are forward-looking statements within the meaning of the federal securities laws. All statements that do not concern historical facts are forward-looking statements and include, among other things, statements about our expectations, beliefs, intentions and/or strategies for the future. These forward-looking statements include statements regarding our future operations, financial condition and prospects, expectations for treatment growth rates, revenue per treatment, expense growth, levels of the provision for uncollectible accounts receivable, operating income, cash flow, operating cash flow, estimated tax rates, capital expenditures, the development of new dialysis centers and dialysis center acquisitions, government and commercial payment rates, revenue estimating risk and the impact of our level of indebtedness on our financial performance, and including earnings per share. These statements involve substantial known and unknown risks and uncertainties that could cause our actual results to differ materially from those described in the forward-looking statements, including but not limited to, risks resulting from the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, which may result in the loss of revenues or patients, a reduction in government payment rates under the Medicare ESRD program or other government-based programs, the impact of the Center for Medicare and Medicaid Services (CMS) 2014 Medicare Advantage benchmark structure, risks arising from potential federal and/or state legislation that could have an adverse effect on our operations and profitability, changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing, legal compliance risks, including our continued compliance with complex government regulations and current or potential investigations by various government entities and related government or private-party proceedings, including risks relating to the resolution of the 2010 and 2011 U.S. Attorney Physician Relationship Investigations, such as restrictions on our business and operations required by a corporate integrity agreement and other settlement terms, and the financial impact thereof, continued increased competition from large and medium-sized dialysis providers that compete directly with us, our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector that may erode our patient base and reimbursement rates such as accountable care organizations (ACOs), independent practice associations (IPAs) and integrated delivery systems, or to businesses outside of dialysis and HCP's business, our ability to complete acquisitions, mergers or dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire or have acquired, including HCP, or to expand our operations and services to markets outside the U.S., variability of our cash flows, the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all, risks arising from the use of accounting estimates, judgments and interpretations in our financial statements, loss of key HCP employees, potential disruption from the HCP transaction making it more difficult to maintain business and operational relationships with customers, partners, associated physicians and physician groups, hospitals and others, the risk that laws regulating the corporate practice of medicine could restrict the manner in which HCP conducts its business, the risk that the cost of providing services under HCP's agreements may exceed our compensation, the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact HCP's business, revenue and profitability, the risk that HCP may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability, the risk that a disruption in HCP's healthcare provider networks could have an adverse effect on HCP's business operations and profitability, the risk that reductions in the quality ratings of health maintenance organization plan customers of HCP could have an adverse effect on HCP's business, or the risk that health plans that acquire health maintenance organizations may not be willing to contract with HCP or may be willing to contract only on less favorable terms, and the other risk factors set forth in Part II, Item 1A. of this Quarterly Report on Form 10-Q. We base our forward-looking statements on information currently

available to us, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

Table of Contents

The following should be read in conjunction with our condensed consolidated financial statements.

Consolidated results of operations

We operate two major divisions, Kidney Care and HealthCare Partners (HCP). Our Kidney Care division is comprised of our U.S. dialysis and related lab services business, our ancillary services and strategic initiatives including our international operations, and our corporate support expenses. Our HCP division is comprised of our HCP business.

Our largest major line of business is our U.S. dialysis and related lab services, which is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as ESRD. Our other major line of business is HCP, which is a patient- and physician-focused integrated health care delivery and management company.

Following is a summary of our consolidated operating results for the second quarter of 2014 compared with the prior sequential quarter and the same quarter of 2013, as well as the six months ended June 30, 2014 compared to the same period in 2013, for reference in the discussion that follows.

	June 30, 2014		Three months ended March 31, 2014		June 30, 2013		Six months ended June 30, 2014		June 30, 2013	
	(dollar amounts rounded to nearest million)									
Net revenues:										
Patient service revenues	\$ 2,187		\$ 2,114		\$ 2,049		\$ 4,301		\$ 4,028	
Less: Provision for uncollectible accounts	(88)		(83)		(72)		(171)		(142)	
Net patient service revenues	2,099		2,031		1,977		4,130		3,886	
Capitated revenues	799		788		710		1,587		1,473	
Other revenues	274		224		185		498		342	
Total consolidated net revenues	3,172	100%	3,043	100%	2,872	100%	6,215	100%	5,701	100%
Operating expenses and charges:										
Patient care costs	2,247	71%	2,180	71%	2,015	70%	4,426	71%	3,975	70%
General and administrative	298	9%	284	9%	268	9%	582	9%	553	10%
Depreciation and amortization	146	5%	142	5%	131	5%	288	5%	256	4%
Provision for uncollectible accounts	3		3		1		6		2	

Equity investment income	(6)		(7)		(8)		(13)		(17)	
Loss contingency reserve									300	5%
Contingent earn-out obligation adjustment					(57)	(2%)			(57)	(1%)
Total operating expenses and charges	2,688	85%	2,602	85%	2,350	82%	5,289	85%	5,012	88%
Operating income	\$ 484	15%	\$ 441	15%	\$ 522	18%	\$ 926	15%	\$ 689	12%

Table of Contents

The following table summarizes consolidated net revenues for our Kidney Care division and our HCP division:

	Three months ended			Six months ended	
	June 30, 2014	March 31, 2014	June 30, 2013	June 30, 2014	June 30, 2013
(dollar amounts rounded to nearest million)					
Net revenues:					
Kidney Care:					
U.S. dialysis and related lab services patient service revenues	\$ 2,106	\$ 2,037	\$ 1,988	\$ 4,142	\$ 3,905
Less: Provision for uncollectible accounts	(84)	(82)	(69)	(166)	(137)
U.S. dialysis and related lab services net patient service revenues	\$ 2,022	\$ 1,955	\$ 1,919	\$ 3,976	\$ 3,768
Other revenues	3	3	3	7	6
Total net U.S. dialysis and related lab services revenues	2,025	1,958	1,922	3,983	3,774
Other Ancillary services and strategic initiatives revenues	229	214	166	442	319
Other Capitated revenues	16	16	18	32	34
Other Ancillary services and strategic initiatives net patient service revenues (less provision for uncollectible accounts)	29	27	16	56	31
Total net other-ancillary services and strategic initiatives revenues	274	257	200	530	384
Elimination of intersegment and division revenues	(14)	(13)	(11)	(26)	(22)
Total Kidney Care net revenues	2,285	2,202	2,111	4,487	4,136
HCP:					
HCP capitated revenues	783	772	693	1,555	1,439
HCP net patient service revenues (less provision for uncollectible accounts)	58	56	49	114	103
Other revenues	46	13	19	59	23
Total net HCP revenues	887	841	761	1,728	1,565
Total consolidated net revenues	\$ 3,172	\$ 3,043	\$ 2,872	\$ 6,215	\$ 5,701

Table of Contents

The following table summarizes consolidated operating income and adjusted consolidated operating income:

	Three months ended			Six months ended	
	June 30, 2014	March 31, 2014	June 30, 2013	June 30, 2014	June 30, 2013
(dollar amounts rounded to nearest million)					
Operating income:					
Kidney Care:					
U.S. dialysis and related lab services	\$ 408	\$ 387	\$ 402	\$ 795	\$ 486
Other Ancillary services and strategic initiatives (losses) income	(2)	2	(7)		(22)
Contingent earn-out obligation adjustment			57		57
Corporate support costs	(4)	(2)	(11)	(5)	(22)
Total kidney care operating income	402	387	441	790	499
HCP services	82	54	81	136	190
Total consolidated operating income	484	441	522	926	689
Reconciliation of non-GAAP measures:					
Add:					
Contingent earn-out obligation adjustment			(57)		(57)
Loss contingency reserve					300
Adjusted consolidated operating income⁽¹⁾	\$ 484	\$ 441	\$ 465	\$ 926	\$ 932

- (1) For the three and six months ended June 30, 2013, we have excluded \$57 million related to an adjustment to decrease HCP's contingent earn-out obligation. In addition, for the six months ended June 30, 2013, we have excluded \$300 million of expenses related to an estimated loss contingency reserve. These are non-GAAP measures and are not intended as substitutes for the GAAP equivalent measures. We have presented these adjusted amounts because management believes that these presentations enhance a user's understanding of our normal consolidated operating income by excluding an unusual adjustment of \$57 million for a decrease in HCP's contingent earn-out obligation and an estimated \$300 million loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations (see Note 9 to the condensed consolidated financial statements). We therefore consider these adjusted consolidated operating income amounts meaningful and comparable to our prior period results.

Consolidated net revenues

Consolidated net revenues for the second quarter of 2014 increased by approximately \$129 million, or approximately 4.2%, as compared to the first quarter of 2014. The increase in consolidated net revenues was primarily due to an increase of approximately \$67 million associated with the U.S. dialysis and related lab services net revenues, principally due to one and a half additional treatment days in the second quarter of 2014 as compared to the first quarter of 2014 and strong non-acquired growth, partially offset by a decrease of \$1 in the average dialysis revenue per treatment mainly due to a seasonal decrease in acute services. In addition, HCP's net operating revenues increased

by approximately \$46 million, mainly from the recognition of additional HCP revenues related to the maintenance of existing physician networks, additional senior capitated members and the timing of revenue from its annual premium reconciliation for senior capitated members which previously occurred in the third quarter of 2013. The increase in consolidated net revenues was also due to an increase of approximately \$17 million associated with our ancillary services and strategic initiatives revenues primarily from additional pharmacy revenues.

Consolidated net revenues for the second quarter of 2014 increased by approximately \$300 million, or approximately 10.4%, as compared to the second quarter of 2013. The increase in consolidated net revenues was mostly due to an increase of \$103 million in the U.S. dialysis and related lab services net revenues, primarily as a

Table of Contents

result of strong volume growth from non-acquired treatment growth in existing and new centers and an increase of \$1 in the average dialysis revenue per treatment, driven by changes in the mix of our government reimbursements and an increase in some of our commercial payment rates. The increase in consolidated net revenues was also due to an increase in HCP net revenues of \$126 million due to acquired growth, an increase in senior capitated members in the second quarter of 2014 and from the recognition of additional HCP revenues related to the maintenance of existing physician networks, as well as the timing of revenue from its annual premium reconciliation for senior capitated members which previously occurred in the third quarter of 2013, partially offset by a reduction in HCP's Medicare Advantage payments. In addition, the increase in consolidated net revenues was also due to an increase of approximately \$74 million in our ancillary services and strategic initiatives, mainly from growth in our pharmacy services and in our international operations.

Consolidated net revenues for the six months ended June 30, 2014 increased by approximately \$514 million, or approximately 9.0%, as compared to the same period in 2013. The increase in consolidated net revenues was primarily due to an increase of \$209 million in the U.S. dialysis and related lab services net revenues, largely as a result of strong volume growth from non-acquired treatment growth in existing and new centers, and an increase in HCP net revenues of \$163 million, primarily due to an increase in senior capitated members in the first quarter of 2014 and from the recognition of additional HCP revenues related to the maintenance of existing physician networks, as well as the timing of revenue from its annual premium reconciliation for senior capitated members which previously occurred in the third quarter of 2013, partially offset by a reduction in HCP's Medicare Advantage payments. In addition, the increase in consolidated net revenues was also due to an increase of approximately \$146 million in our ancillary services and strategic initiatives, largely due to growth in our pharmacy services and in our international operations.

Consolidated operating income

Consolidated operating income for the second quarter of 2014 increased by approximately \$43 million, or approximately 9.8%, as compared to the first quarter of 2014. The increase in the consolidated operating income was for the most part due to an increase in U.S. dialysis and related lab services net revenues due to strong volume growth primarily from one and a half additional treatment days in the second quarter of 2014 as compared to the first quarter of 2014, lower payroll taxes, improved productivity, as well as improved operating results in HCP mainly from the recognition of additional revenues as described above, and an increase in HCP senior capitated members. Consolidated operating income was negatively impacted by an increase in pharmaceutical costs, an increase in the intensities of physician prescribed pharmaceuticals, higher labor costs, an increase in travel costs for management meetings, higher long-term incentive compensation and an increase in HCP's medical claims expense as a result of additional senior and Medicaid members who have higher utilization.

Consolidated operating income for the second quarter of 2014 decreased by approximately \$38 million, or approximately 7.3%, as compared to the second quarter of 2013, including the contingent earn-out obligation adjustment of \$57 million in the second quarter of 2013. Excluding this item, adjusted consolidated operating income would have increased by \$19 million. The increase in adjusted consolidated operating income was primarily due to strong volume growth in the number of treatments from non-acquired growth and acquisitions, and from improved productivity. In addition, adjusted consolidated operating income was also positively impacted by improved operating performance of certain ancillary services and strategic initiatives, mainly our pharmacy services, and the recognition of additional HCP revenues as described above, partially offset by the impact of lower HCP Medicare Advantage payments, an increase in HCP's medical claims expenses as a result of additional senior capitated members, higher pharmaceutical unit costs, an increase in the intensities of physician-prescribed pharmaceuticals, an increase in the provision for uncollectible accounts, higher labor costs and related payroll taxes, and higher long-term incentive compensation.

Consolidated operating income for the six months ended June 30, 2014 increased by approximately \$237 million, or approximately 34.4%, as compared to the same period in 2013, which includes the accrued estimated loss contingency reserve of \$300 million and the contingent earn-out obligation adjustment of \$57 million.

Table of Contents

Excluding these items, adjusted consolidated operating income would have decreased by \$6 million. The decrease in adjusted operating income was primarily due to the impact of lower HCP operating results, largely from lower Medicare Advantage payments, partially offset by the recognition of additional HCP revenues as described above. In addition, the decrease in adjusted consolidated operating income was also due to higher pharmaceutical unit costs, an increase in the intensities of physician-prescribed pharmaceuticals, an increase in the provision for uncollectible accounts, higher labor costs and related payroll taxes, an increase in benefit costs, higher long-term incentive compensation and an increase in HCP's medical claims expenses, as a result of additional senior capitated members. The decrease in adjusted consolidated operating income was partially offset by strong volume growth in the number of treatments from non-acquired growth, improved productivity and lower professional fees for legal and compliance matters. In addition, adjusted consolidated operating income was also positively impacted by improved operating performance of certain ancillary services and strategic initiatives, primarily from growth in our pharmacy services.

U.S. dialysis and related lab services business***Results of operations***

	Three months ended			Six months ended	
	June 30, 2014	March 31, 2014	June 30, 2013	June 30, 2014	June 30, 2013
	(dollar amounts rounded to nearest million,				
	except per treatment data)				
Net revenues:					
Dialysis and related lab services patient service revenues	\$ 2,106	\$ 2,037	\$ 1,988	\$ 4,142	\$ 3,905
Less: Provision for uncollectible accounts	(84)	(82)	(69)	(166)	(137)
Dialysis and related lab services net patient service revenues	\$ 2,022	\$ 1,955	\$ 1,919	\$ 3,976	\$ 3,768
Other revenues	3	3	3	7	6
Total net dialysis and related lab services revenues	\$ 2,025	\$ 1,958	\$ 1,922	\$ 3,983	\$ 3,774
Operating expenses and charges:					
Patient care costs	1,358	1,323	1,265	2,680	2,482
General and administrative	164	155	169	319	338
Depreciation and amortization	99	96	89	196	174
Loss contingency reserve					300
Equity investment income	(4)	(3)	(3)	(7)	(6)

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Total operating expenses and charges	1,617	1,571	1,520	3,188	3,288
Operating income	\$ 408	\$ 387	\$ 402	\$ 795	\$ 486
Dialysis treatments	6,196,394	5,975,627	5,867,973	12,172,021	11,496,772
Average dialysis treatments per treatment day	79,441	78,215	75,230	78,834	74,413
Average dialysis and related lab services revenue per treatment	\$ 340	\$ 341	\$ 339	\$ 340	\$ 340

Net revenues

Dialysis and related lab services net revenues for the second quarter of 2014 increased by approximately \$67 million, or approximately 3.4%, as compared to the first quarter of 2014. The increase in dialysis and related lab services net revenues was due to an increase in the number of treatments as a result of one and a half

Table of Contents

additional treatment days in the second quarter of 2014 as compared to the first quarter of 2014 and strong non-acquired treatment growth in existing and new centers, partially offset by a decrease in the average dialysis revenue per treatment of approximately \$1. The decrease in the average dialysis revenue per treatment was primarily due to a seasonal decrease in our acute services, partially offset by an increase in our commercial mix and an increase in some of our commercial payment rates.

Dialysis and related lab services net revenues for the second quarter of 2014 increased by approximately \$103 million, or approximately 5.4%, as compared to the second quarter of 2013. The increase in net revenues in the second quarter of 2014 was principally due to strong volume growth from additional treatments. The increase in the number of treatments was primarily attributable to strong non-acquired treatment growth at existing and new centers. The average dialysis revenue per treatment also increased by approximately \$1 in the second quarter of 2014 as compared to the second quarter of 2013. The increase in our average dialysis revenue per treatment was primarily due to an increase as a result of changes in the mix of our government reimbursements and an increase in some of our average commercial payment rates, partially offset by a decrease in our commercial mix and an increase in the provision for uncollectible accounts.

Dialysis and related lab services net revenues for the six months ended June 30, 2014 increased by approximately \$209 million, or approximately 5.5%, as compared to the same period in 2013. The increase in net revenues in the first six months of 2014 was principally due to strong volume growth from additional treatments. The increase in the number of treatments was primarily attributable to strong non-acquired treatment growth at existing and new centers. The average dialysis revenue per treatment was flat in the first six months of 2014 as compared to the first six months of 2013, but was impacted by an increase in our acute services and an increase in some of our average commercial payment rates, offset by a decrease in our Medicare reimbursements as a result of sequestration that went into effect on April 1, 2013, and a slight decrease in our commercial mix. Dialysis and related lab services net revenues were also negatively impacted by an increase in the provision for uncollectible accounts.

Provision for uncollectible accounts. The provision for uncollectible accounts receivable for dialysis and related lab services was 4.0% for the second quarter of 2014, 4.0% for the first quarter of 2014, and 3.5% for the second quarter of 2013. We continue to experience higher amounts of non-covered Medicare write-offs. We assess our level of the provision for uncollectible accounts based upon our historical cash collection experience and trends, and have and will continue to adjust the provision as necessary as a result of changes in our cash collections.

Medicare update

CMS issued the 2014 final rule for the ESRD Prospective Payment System (PPS), which phases in over three to four years the 12% cut mandated by the American Taxpayer Relief Act of 2012 (ATRA). Although no reimbursement reduction is expected in 2015 under the final ESRD PPS rule, it is anticipated that future reductions will occur no later than 2017. However, the recent Protecting Access to Medicare Act that was passed on March 31, 2014 further modified the reduction to only 1.25% in 2016 and 2017, and 1% in 2018. While this modification eases reimbursement pressure, future legislative actions could have the opposite effect. CMS recently issued the 2015 proposed rule for ESRD PPS, which was published in the Federal Register on July 11, 2014. The proposed rule would increase payments to dialysis facilities modestly by 0.3% to 0.5%, although rural facilities would receive a decrease of 0.5%.

The Protecting Access to Medicare Act was passed by Congress on March 31, 2014 which delayed the implementation of oral-only medications that will be included in the bundled ESRD payment rate to dialysis centers until June 1, 2024.

As previously disclosed, sequestration spending cuts took effect on April 1, 2013, which reduced our Medicare payments by 2%. These spending cuts were extended through 2014 and 2015 by a two-year funding bill signed into law on December 31, 2013, which will continue to negatively impact our condensed consolidated financial results.

Table of Contents

Operating expenses and charges

Patient care costs. Dialysis and related lab services patient care costs of approximately \$219 per treatment for the second quarter of 2014 decreased by \$2 as compared to the first quarter of 2014. The decrease in patient care costs per treatment was primarily due to a decrease in benefit costs and related payroll taxes, improved productivity and a decrease in seasonal occupancy costs, partially offset by an increase in travel expenses related to management meetings, higher pharmaceutical unit costs and an increase in professional fees.

Dialysis and related lab services patient care costs on a per treatment basis for the second quarter of 2014 increased by approximately \$3 as compared to the second quarter of 2013. The increase was primarily attributable to higher labor costs, higher pharmaceutical unit costs, higher occupancy costs, an increase in our other direct operating expenses associated with our dialysis centers and an increase in intensities of physician-prescribed pharmaceuticals, partially offset by improved productivity and lower benefit costs.

Dialysis and related lab services patient care costs on a per treatment basis for the six months ended June 30, 2014 increased by approximately \$4 as compared to the same period in 2013. The increase was primarily attributable to higher labor costs, an increase in benefit costs, higher pharmaceutical unit costs, higher occupancy costs, an increase in our other direct operating expenses associated with our dialysis centers and an increase in intensities of physician-prescribed pharmaceuticals, partially offset by improved productivity.

General and administrative expenses. Dialysis and related lab services general and administrative expenses of approximately \$164 million in the second quarter of 2014 increased by approximately \$9 million as compared to the first quarter of 2014. The increase in general and administrative expenses was primarily due to higher labor and benefit costs, an increase in travel expenses related to management meetings and higher long-term incentive compensation, partially offset by lower payroll taxes and lower professional fees.

Dialysis and related lab services general and administrative expenses for the second quarter of 2014 decreased by approximately \$5 million as compared to the second quarter of 2013. The decrease was primarily due to lower labor costs, lower travel expenses and a decrease in professional fees for legal matters, partially offset by higher long-term incentive compensation.

Dialysis and related lab services general and administrative expenses for the six months ended June 30, 2014 decreased by approximately \$19 million as compared to the same period in 2013. The decrease was primarily due to lower labor costs, lower travel expenses, a decrease in professional fees for compliance matters and information technology initiatives, partially offset by higher long-term incentive compensation.

Depreciation and amortization. Depreciation and amortization for dialysis and related lab services was approximately \$99 million for the second quarter of 2014, \$96 million for the first quarter of 2014 and \$89 million for the second quarter of 2013. The increases in depreciation and amortization in the second quarter of 2014, as compared to the first quarter of 2014 and the second quarter of 2013, were primarily due to growth in newly developed centers and from acquired centers.

Depreciation and amortization for dialysis and related lab services was approximately \$196 million for the six months ended June 30, 2014 as compared to \$174 million for the same period in 2013. The increase was primarily due to the same factors as described above.

Loss contingency reserve. We have previously agreed to a framework for a global resolution with the United States Attorney's Office for the District of Colorado, the Civil Division of the United States Department of Justice and the

Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation for both the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above. The settlement will include payment of approximately \$389 million. The final settlement remains subject to negotiation of specific terms. During 2013,

Table of Contents

in connection with offers to settle these matters, we accrued a total of \$397 million as an estimated loss contingency reserve, \$300 million in the first quarter of 2013 and \$97 million in the third quarter of 2013.

Equity investment income. Equity investment income for dialysis and related lab services was approximately \$4.1 million for the second quarter of 2014, as compared to \$2.7 million for the first quarter of 2014 and \$2.8 million for the second quarter of 2013. The increase in equity investment income in the second quarter of 2014 as compared to the first quarter of 2014, and the first quarter of 2013, was primarily due to an increase in the profitability of certain joint ventures in the second quarter of 2014.

Accounts receivable

Our dialysis and related lab services accounts receivable balances at June 30, 2014 and March 31, 2014 were \$1,148 million and \$1,168 million, respectively, which represented approximately 53 days and 55 days, respectively, which is net of the provision for uncollectible accounts. Our DSO calculation is based on the current quarter's average revenues per day. There were no significant changes during the second quarter of 2014 from the first quarter of 2014 in the amount of unreserved accounts receivable over one year old or the amounts pending approval from third-party payors.

Segment operating income

Dialysis and related lab services' operating income for the second quarter of 2014 increased by approximately \$21 million, or approximately 5.4%, as compared to the first quarter of 2014. Operating income increased primarily due to strong volume growth in the number of treatments due to one and a half additional treatment days in the second quarter of 2014 as compared to the first quarter of 2014 and strong non-acquired growth in existing and new centers. Dialysis and related lab services operating income also increased as a result of lower payroll taxes, a decrease in occupancy costs and improved productivity, partially offset by higher pharmaceutical unit costs, an increase in the intensities of physician-prescribed pharmaceuticals, an increase in direct medical supply expense, an increase in long-term incentive compensation and an increase in travel expenses for management meetings.

Dialysis and related lab services' operating income for the second quarter of 2014 increased by approximately \$6 million, or approximately 1.5%, as compared to the second quarter of 2013. The increase is primarily attributable to strong volume growth in revenues from additional treatments as a result of non-acquired treatment growth in existing and new centers, lower travel expenses for management meetings, a decrease in professional fees and improved productivity. Dialysis and related lab services operating income was negatively impacted by higher labor costs, higher pharmaceutical unit costs, an increase in the intensities of physician-prescribed pharmaceuticals, an increase in the provision for uncollectible accounts and an increase in long-term incentive compensation.

Dialysis and related lab services' operating income for the six months ended June 30, 2014 increased by approximately \$309 million, or approximately 63.6%, as compared to the same period in 2013, including the accrued estimated legal contingency reserve of \$300 million in the first quarter of 2013. Excluding this item from the first six months of 2013, adjusted operating income would have increased by \$9 million, primarily attributable to strong volume growth in revenues from additional treatments as a result of non-acquired treatment growth in existing and new centers, and improved productivity. Adjusted dialysis and related lab services operating income was negatively impacted by higher labor costs and related payroll taxes, higher benefit costs, higher pharmaceutical unit costs, an increase in the intensities of physician-prescribed pharmaceuticals, an increase in occupancy costs and an increase in the provision for uncollectible accounts.

Table of Contents*HCP business**Results of operations*

	Three months ended						Six months ended			
	June 30, 2014		March 31, 2014		June 30, 2013		June 30, 2014		June 30, 2013	
	(dollar amounts rounded to nearest millions)									
Net revenues:										
HCP capitated revenue	\$ 783	88%	\$ 772	92%	\$ 693	91%	\$ 1,555	90%	\$ 1,439	92%
Patient service revenue	62		58		52		119		109	
Less: Provision for uncollectible accounts	(4)		(2)		(3)		(5)		(6)	
Net patient service revenue	58	7%	56	7%	49	7%	114	7%	103	7%
Other revenues	46	5%	13	1%	19	2%	59	3%	23	1%
Total net revenues	\$ 887	100%	\$ 841	100%	\$ 761	100%	\$ 1,728	100%	\$ 1,565	100%
Operating expense:										
Patient care costs	\$ 688	77%	\$ 672	80%	\$ 590	78%	\$ 1,360	78%	\$ 1,185	76%
General and administrative expense	77	9%	78	9%	56	7%	155	9%	125	8%
Depreciation and amortization	42	5%	42	5%	39	5%	84	5%	76	5%
Equity investment income	(2)		(5)	(1)%	(5)	(1)%	(7)		(11)	(1)%
Total expenses	805	91%	787	93%	680	89%	1,592	92%	1,375	88%
Operating income	\$ 82	9%	\$ 54	7%	\$ 81	11%	\$ 136	8%	\$ 190	12%

Capitated membership information

The following table provides (i) the total number of capitated members to whom HCP provided healthcare services as of June 30, 2014, March 31, 2014 and June 30, 2013, and (ii) the aggregate member months for the six months ended June 30, 2014, March 31, 2014 and June 30, 2013. Member months represent the aggregate number of months of healthcare services HCP has provided to capitated members during a period of time:

Members at

**Members months for
Three months ended**

	June 30, 2014	March 31, 2014	June 30, 2013	June 30, 2014	March 31, 2014	June 30, 2013
HCP total capitated membership	828,500	795,300	733,300	2,455,700	2,373,000	2,209,000

In addition to the members above, HCP provided healthcare services to members of Magan Medical Group, an unconsolidated joint venture that is accounted for as an equity investment. The Magan Medical Group joint venture provided health care services for approximately 44,800 members as of June 30, 2014 and for approximately 133,600 member months for the quarter ended June 30, 2014.

The increase in members and member months was primarily attributable to an increase in senior members resulting from new acquisitions and non-acquired growth, partially offset by a decline in commercial members resulting from the state of California discontinuing the Healthy Families program.

Table of Contents*Revenues*

The following table provides HCP's revenue by source:

	Three months ended						Six months ended			
	June 30, 2014		March 31, 2014		June 30, 2013		June 30, 2014		June 30, 2013	
(dollars rounded to nearest millions)										
HCP revenues:										
Commercial revenues	\$ 177	20%	\$ 187	22%	\$ 176	23%	\$ 363	21%	\$ 357	23%
Senior revenues	576	65%	565	67%	496	65%	1,141	66%	1,048	67%
Medicaid revenues	30	3%	20	3%	21	3%	51	3%	34	2%
Total capitated revenues	\$ 783	88%	\$ 772	92%	\$ 693	91%	\$ 1,555	90%	\$ 1,439	92%
Patient service revenue, net of provision for uncollectible accounts	58	7%	56	7%	49	7%	114	7%	103	7%
Other revenues	46	5%	13	1%	19	2%	59	3%	23	1%
Total net revenues	\$ 887	100%	\$ 841	100%	\$ 761	100%	\$ 1,728	100%	\$ 1,565	100%

Net revenues

HCP's net revenue for the second quarter of 2014 increased by \$46 million, or approximately 5.5%, as compared to the first quarter of 2014. The increase in revenue was primarily attributable to an increase in senior capitated members, an increase in Medicaid membership, the timing of revenue associated with HCP's annual premium reconciliation of senior capitated members, which previously occurred in the third quarter of 2013, and from the recognition of additional HCP revenues related to the maintenance of existing physician networks.

HCP's net revenue for the second quarter of 2014 increased by \$126 million, or approximately 16.6%, as compared to the second quarter of 2013. The increase in revenue was primarily attributable to an increase in the number of senior capitated members from acquired and organic growth, an increase in Medicaid membership, the timing of revenue associated with HCP's annual premium reconciliation of senior capitated members which previously occurred in the third quarter of 2013 and from the recognition of additional HCP revenues related to the maintenance of existing physician networks, partially offset by a decrease in Medicare Advantage rates, and a decline in the number of commercial members to whom HCP provides health care services.

HCP's net revenue for the six months ended June 30, 2014 increased by \$163 million, or approximately 10.4%, as compared to the same period in 2013. The increase in revenue was primarily attributable to an increase in the number of senior capitated members from acquired and organic growth, an increase in Medicaid membership, the timing of revenue associated with HCP's annual premium reconciliation of senior capitated members which previously occurred in the third quarter of 2013 and from the recognition of additional HCP revenues related to the maintenance of existing physician networks, partially offset by a decrease in Medicare Advantage rates, a reduction in Medicare rates due to sequestration and a decline in the number of commercial members to whom HCP provides health care services.

On April 7, 2014 CMS issued final guidance for 2015 Medicare Advantage rates, which incorporated a re-blending of the risk adjustment models which CMS utilizes to determine risk acuity scores of Medicare Advantage patients. We estimate that the final cumulative impact of the 2015 rate structure represents an increase of up to approximately 0.4% of HCP's average revenues it manages on behalf of its senior capitated population as compared to 2014, instead of a decrease of 1.9% that was originally proposed by CMS in February 2014.

Operating expenses

HCP's patient care costs of approximately \$688 million for the second quarter of 2014, increased by approximately \$16 million, or approximately 2.4%, as compared to the first quarter of 2014. The increase is primarily attributable to the increase in medical claim expenses due to acquisitions and higher utilization, including an increase in higher dollar claims.

Table of Contents

HCP's patient care costs of approximately \$688 million for the second quarter of 2014, increased by approximately \$98 million, or approximately 16.6%, as compared to the second quarter of 2013. The increase was primarily attributable to the same factors as described for the increase in the second quarter of 2014 as compared to the first quarter of 2014.

HCP's patient care costs of approximately \$1,360 million for the six months ended June 30, 2014, increased by approximately \$175 million, or approximately 14.8%, as compared to the same period in 2013. The increase was primarily attributable to the same factors as described for the increase in the second quarter of 2014 as compared to the first quarter of 2014.

HCP's general and administrative costs of approximately \$77 million for the second quarter of 2014, was relatively flat as compared to the first quarter of 2014.

HCP's general and administrative costs of approximately \$77 million for the second quarter of 2014, increased by approximately \$21 million, or approximately 37.5%, as compared to the second quarter of 2013. The increase in general and administrative expenses was primarily attributable to increases in corporate support departments to accommodate additional acquisitions and changes in our estimated accruals related to acquired entities in the second quarter of 2013.

HCP's general and administrative costs of approximately \$155 million for the six months ended June 30, 2014, increased by approximately \$30 million, or approximately 24.0%, as compared to the same period in 2013. The increase in general and administrative expenses was primarily attributable to increases in corporate support departments to accommodate additional acquisitions and changes in our estimated accruals related to acquired entities in the second quarter of 2013.

HCP's depreciation and amortization of approximately \$42 million for the second quarter of 2014 was relatively flat as compared to the first quarter of 2014. Depreciation and amortization is primarily based upon the fair value of equipment, leasehold improvements and intangible assets we recognized in the HCP acquisition and subsequent acquisitions.

HCP's depreciation and amortization of approximately \$42 million for the second quarter of 2014 increased by approximately \$3 million, as compared to the second quarter of 2013, primarily attributable to depreciation and amortization of acquired assets associated with acquisitions.

HCP's depreciation and amortization of approximately \$84 million for the six months ended June 30, 2014 increased by approximately \$8 million, as compared to the same period in 2013, primarily attributable to depreciation and amortization of acquired assets associated with acquisitions.

Segment operating income

HCP's operating income for second quarter of 2014 increased by approximately \$28 million, or approximately 51.9%, as compared to the first quarter of 2014. The increase was primarily attributable to an increase in our senior capitated members, an increase in Medicaid membership, an increase in revenue associated with HCP's annual premium reconciliation of senior capitated members and from the recognition of additional HCP revenues related to the maintenance of existing physician networks, partially offset by a reduction in the number of commercial members and higher medical claims expenses.

For the three months ended June 30, 2014, HCP's operating income included approximately \$12 million of operating income related to the physician owned entities (physician groups).

HCP's operating income for second quarter of 2014 was relatively flat as compared to the second quarter of 2013.

Table of Contents

HCP's operating income for six months ended June 30, 2014 decreased by approximately \$54 million, or approximately 28.4%, as compared to the same period in 2013. The decrease was primarily attributable to a decrease in Medicare Advantage payments, a decrease in commercial memberships and higher medical claims expense, partially offset by an increase in our senior capitated members, an increase in Medicaid membership, an increase in revenue associated with HCP's annual premium reconciliation of senior capitated members and from the recognition of additional HCP revenues related to the maintenance of existing physician networks.

For the six months ended June 30, 2014, HCP's operating income included approximately \$20 million of operating income associated with the physician groups.

Other Ancillary services and strategic initiatives business

Our other operations include ancillary services and strategic initiatives which are primarily aligned with our core business of providing dialysis services to our network of patients. As of June 30, 2014 these consisted primarily of pharmacy services, disease management services, vascular access services, ESRD clinical research programs, physician services, direct primary care and our international dialysis operations. The ancillary services and strategic initiatives generated approximately \$274 million of net revenues in the second quarter of 2014, representing approximately 8.5% of our consolidated net revenues. We currently expect to continue to invest in our ancillary services and strategic initiatives, including our continued expansion into certain international markets as we work to develop successful new business operations in the U.S. as well as outside the U.S. However, any significant change in market conditions, business performance or the regulatory environment may impact the economic viability of any of these strategic initiatives. Any unfavorable changes in these strategic initiatives could result in a write-off or an impairment of some or all of our investments, including goodwill and could also result in significant termination costs if we were to exit a particular line of business.

As of June 30, 2014, we provided dialysis and administrative services to a total of 84 outpatient dialysis centers located in ten countries outside of the U.S. The total net revenues generated from our international operations are provided below.

The following table reflects the results of operations for the ancillary services and strategic initiatives:

	Three months ended			Six months ended	
	June 30, 2014	March 31, 2014	June 30, 2013	June 30, 2014	June 30, 2013
	(dollar amounts rounded to nearest millions)				
U.S. revenues					
Net patient service revenues	\$ 5	\$ 4	\$ 3	\$ 9	\$ 6
Other revenues	227	212	164	439	317
Capitated revenues	16	16	18	32	34
Total	248	232	185	480	357
International revenues					
Net patient service revenues	24	23	13	47	24
Other revenues	2	2	2	3	3
Total	26	25	15	50	27

Total net revenues	\$ 274	\$ 257	\$ 200	\$ 530	\$ 384
Total operating (loss) income	\$ (2)	\$ 2	\$ (7)	\$	\$ (22)

Net revenues

The ancillary services and strategic initiatives net revenues for the second quarter of 2014 increased by approximately \$17 million or 6.6% as compared to the first quarter of 2014. The increase was primarily from growth in prescriptions dispensed as part of our pharmacy services.

Table of Contents

The ancillary services and strategic initiatives net revenues for the second quarter of 2014 increased by approximately \$74 million, or 37.0%, as compared to the second quarter of 2013. The increase was primarily from growth in prescriptions dispensed as part of our pharmacy services and growth in our international operations.

The ancillary services and strategic initiatives net revenues for the six months ended June 30, 2014 increased by approximately \$146 million, or 38.0%, as compared to the same period in 2013. The increase was primarily from growth in prescriptions dispensed as part of our pharmacy services and growth in our international operations.

Operating expenses

Ancillary services and strategic initiatives operating expenses for the second quarter of 2014 increased by approximately \$21 million as compared to the first quarter of 2014. The increase in operating expenses was primarily due to an increase in volume in our pharmacy business, increased expenses related to our disease management services and an increase in expenses associated with our international dialysis expansion.

Ancillary services and strategic initiatives operating expenses for the second quarter of 2014 increased by approximately \$69 million as compared to the second quarter of 2013. The increase in operating expenses was primarily due to an increase in volume in our pharmacy business, an increase in expenses associated with our international dialysis expansion into Europe, South America and Asia Pacific, an increase in labor costs and related payroll taxes and an increase in benefit costs.

Ancillary services and strategic initiatives operating expenses for the six months ended June 30, 2014 increased by approximately \$124 million as compared to the same period in 2013. The increase in operating expenses was primarily due to an increase in volume in our pharmacy business, an increase in expenses associated with our international dialysis expansion into Europe, South America and Asia Pacific, an increase in professional fees, higher labor costs and related payroll taxes and an increase in benefit costs.

Ancillary services and strategic initiatives operating income (loss)

Ancillary services and strategic initiatives operating income for the second quarter of 2014 decreased by approximately \$4 million from the first quarter of 2014. The decrease in operating income was primarily due to an increase in costs associated with international dialysis expansion and an increase in claims expenses related to our disease management services, partially offset by improved operating performance in our pharmacy business.

Ancillary services and strategic initiatives operating losses for the second quarter of 2014 decreased by approximately \$5 million from the second quarter of 2013. The decrease in operating losses was primarily due to improved operating performance of our pharmacy business related to increased prescriptions dispensed, partially offset by an increase in costs associated with international dialysis expansion, an increase in claims expenses related to our disease management services, an increase in labor costs and related payroll taxes, and an increase in benefit costs.

Ancillary services and strategic initiatives operating losses for the six months ended June 30, 2014 decreased by approximately \$22 million from the same period in 2013. The decrease in operating losses was primarily due to improved operating performance of our pharmacy business related to increased prescriptions dispensed, partially offset by an increase in labor costs and related payroll taxes, and an increase in benefit costs.

Corporate-level charges

Debt expense. Debt expense of \$106.1 million was relatively flat in the second quarter of 2014 as compared to the first quarter of 2014.

Table of Contents

Debt expense in the second quarter of 2014 decreased by approximately \$2 million primarily due to lower average outstanding principal balances, as compared to the second quarter of 2013.

Our overall weighted average effective interest rate for the second quarter of 2014 was 4.85% compared to 4.89% for the first quarter of 2014 and 4.86% for the second quarter of 2013.

For the six months ended June 30, 2014, debt expense of \$212.5 million decreased by approximately \$1.5 million, primarily due to lower average outstanding principal balances, as compared to the same period in 2013.

Corporate support costs. Corporate support costs consist primarily of labor, benefits and long-term incentive compensation costs for departments which provide support to all of our different operating lines of business. Corporate support costs were approximately \$3.8 million in the second quarter of 2014, \$1.1 million in the first quarter of 2014 and \$11.0 million in second quarter of 2013. These expenses are included in our consolidated general and administrative expenses. The increase in corporate support costs in the second quarter of 2014 as compared to the first quarter of 2014 was primarily due to higher long-term incentive compensation. The decrease in corporate support costs in the second quarter of 2014 as compared to the second quarter of 2013 was primarily from internal management fees paid by our ancillary lines of businesses related to the licensing and the right to use newly developed intellectual property and other corporate level services.

Corporate support costs were approximately \$4.9 million in the six months ended June 30, 2014, as compared to \$22.4 million for the same period in 2013. These expenses are included in our consolidated general and administrative expenses. The decrease in corporate support costs were primarily due to the same reasons as noted above for the change in the second quarter of 2014 as compared to the second quarter of 2013.

Other income. Other income for the second quarter of 2014 was \$1.7 million as compared to \$1.7 million for the first quarter of 2014 and a loss of (\$1.4) million for the second quarter of 2013. The increase in other income in the second quarter of 2014 as compared to the second quarter of 2013 was primarily related to the sale of certain investments at a loss during the second quarter of 2013.

Noncontrolling interests

Net income attributable to noncontrolling interests was \$33.7 million for the second quarter of 2014 as compared to \$28.4 million for the first quarter of 2014, and \$29.0 million for the second quarter of 2013. The increases in net income attributable to noncontrolling interests in the second quarter of 2014, as compared to both the first quarter of 2014 and the second quarter of 2013, was primarily due to the overall number of joint ventures and an increase in the overall profitability of certain of our dialysis joint ventures.

Accounts receivable

Our consolidated total accounts receivable balances at June 30, 2014 and March 31, 2014 were \$1,550 million and \$1,540 million, respectively, which represented approximately 46 and 47 days of revenue, respectively, which is net of the provision for uncollectible accounts.

Outlook

We are updating our consolidated operating income guidance for 2014 to now be in the range of \$1.755 billion to \$1.840 billion. Our previous consolidated operating income guidance for 2014 was in the range of \$1.725 billion to \$1.840 billion.

We are also updating our operating income guidance for our Kidney Care division for 2014 to now be in the range of \$1.550 billion to \$1.600 billion. Our previous operating income guidance for Kidney Care for 2014 was in the range of \$1.520 billion to \$1.580 billion.

Table of Contents

We are lowering the high end of our operating income guidance for HCP for 2014 to now be in the range of \$205 million to \$240 million. Our previous operating income guidance for HCP for 2014 was in the range of \$205 million to \$260 million.

We still expect our consolidated operating cash flow for 2014 to be in the range of \$1.450 billion to \$1.550 billion.

The consolidated cash flow amounts for 2014 exclude any potential payment relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations.

These projections and the underlying assumptions involve significant risks and uncertainties, and actual results may differ materially from these current projections. See page 41 for further details regarding our forward looking statements.

Liquidity and capital resources

Liquidity and capital resources. Cash flow from operations during the second quarter of 2014 was \$262 million, compared to \$307 million during the second quarter of 2013. Cash flow from operations in the second quarter of 2014 decreased as a result of a decline in cash collections and the timing of certain other working capital items, partially offset by lower income tax payments. Non-operating cash outflows for the second quarter of 2014 included capital asset expenditures of \$152 million, including \$88 million for new center developments and relocations and \$64 million for maintenance and information technology. In addition, we spent \$31 million for acquisitions and we paid distributions to noncontrolling interests of \$33 million in that period. Non-operating cash outflows for the second quarter of 2013 included capital asset expenditures of \$142 million, including \$84 million for new center developments and relocations and \$58 million for maintenance and information technology. In addition, we spent \$61 million for acquisitions and we paid distributions to noncontrolling interests of \$30 million in that period.

Cash flow from operations for the six months ended June 30, 2014 was \$681 million, compared to \$686 million during the same period in 2013. Cash flow from operations in 2014 decreased as a result of a decline in cash collections and the timing of certain working capital items. Non-operating cash outflows during the six months ended June 30, 2014, included capital asset expenditures of \$279 million, including \$165 million for new center developments and relocations and \$114 million for maintenance and information technology. In addition, we spent \$98 million for acquisitions and we paid distributions to noncontrolling interests of \$66 million in that period. Non-operating cash outflows during the six months ended June 30, 2013, included capital asset expenditures of \$258 million, including \$154 million for new center developments and relocations and \$104 million for maintenance and information technology. In addition, we spent \$152 million for acquisitions and we paid distributions to noncontrolling interests of \$65 million in that period.

During the second quarter of 2014, our U.S. dialysis and related lab services business opened 22 dialysis centers and provided management and administrative services to one less dialysis center. In addition, our international dialysis operations acquired three dialysis centers, opened six dialysis centers, closed one dialysis center and provided management and administrative services to one additional center. During the second quarter of 2013, we acquired a total of three dialysis centers, opened 18 dialysis centers, merged one center into one other existing center, sold two centers and provided management and administrative services to one additional center located in the U.S. In addition, we also acquired a total of eight centers and closed one center outside of the U.S.

During the six months ended June 30, 2014, our U.S. dialysis and related lab services business acquired a total of one dialysis center, opened 46 dialysis centers and merged two dialysis centers into other existing dialysis centers. In addition, our international dialysis operations acquired three dialysis centers, opened seven dialysis centers, closed

two dialysis centers and provided management and administrative services to three additional

Table of Contents

centers. During the six months ended June 30, 2013, we acquired a total of 11 dialysis centers, opened 45 dialysis centers, merged two centers into other existing centers, sold two centers and provided management and administrative services to four additional centers located in the U.S. In addition, we also acquired and opened a total of 12 centers and provided management and administrative service to one additional center outside of the U.S., four of which we provide management and administrative services to, which we consolidate under applicable accounting standards.

During the second quarter of 2014, our HCP business acquired one primary care physician practice and two private medical practices. During the six months ended June 30, 2014, our HCP business acquired one management services organization, six private medical practices, one family practice and two primary care physician practices. During the second quarter of 2013, our HCP business acquired two primary care physician practices and one oncology services center. During the six months ended June 30, 2014, our HCP business acquired two primary care physician practices, one oncology services center and one hospice care services business.

During the first six months of 2014, we made mandatory principal payments under our then existing Senior Secured Credit Facilities (before entering into a new senior secured credit agreement and repaying all outstanding amounts under the then existing Senior Secured Credit Facilities) totaling \$37.5 million on the Term Loan A, \$16.9 million on the Term Loan A-3, \$4.4 million on the Term Loan B and \$4.1 million on the Term Loan B-2.

In June 2014, we entered into a \$5,500 million senior secured credit agreement (the New Credit Agreement). The New Credit Agreement consists of a five year Revolving Credit Facility in the aggregate principal amount of \$1,000 million (the New Revolver), a five year Term Loan A facility in the aggregate principal amount of \$1,000 million (the New Term Loan A) and a seven year Term Loan B facility in the aggregate principal amount of \$3,500 million (the New Term Loan B and collectively with the New Revolver and the New Term Loan A, the New Loans). In addition, we can increase the existing revolving commitments and enter into one or more incremental term loan facilities in an amount not to exceed the sum of \$1,500 million (less the amount of other permitted indebtedness incurred or issued in reliance on such amount), plus an amount of indebtedness such that the senior secured leverage ratio is not in excess of 3.50 to 1.00 after giving effect to such borrowings. The New Revolver and the New Term Loan A initially bears interest at LIBOR plus an interest rate margin of 1.75% which is subject to adjustment depending upon our leverage ratio and can range from 1.50% to 2.00%. The New Term Loan A requires annual principal payments beginning on September 30, 2014 of \$25 million in 2014, \$50 million in 2015, \$62.5 million in 2016, \$87.5 million in 2017, and \$100 million in 2018 with the balance of \$675 million due in 2019. The New Term Loan B bears interest at LIBOR (Floor of 0.75%) plus an interest rate margin of 2.75%. The New Term Loan B requires annual principal payments of \$17.5 million in 2014, and \$35 million for each year from 2015 through 2020, with the balance of \$3,272.5 million due in 2021. These New Loans under the New Credit Agreement are guaranteed by certain of our direct and indirect wholly-owned domestic subsidiaries holding most of our domestic assets and are secured by substantially all of DaVita HealthCare Partners Inc.'s and the guarantors' assets. The New Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on the amount of investments, acquisitions, the payment of dividends and redemptions and the incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as our leverage ratio is below 3.50 to 1.00. In addition, the New Credit Agreement places limitations on the amount of tangible net assets of the non-guarantor subsidiaries and also requires compliance with a maximum leverage ratio covenant.

In addition, in June 2014, we issued \$1,750 million 5 1/8% Senior Notes due 2024 (the 5 1/8% Senior Notes). The 5 1/8% Senior Notes pay interest on January 15 and July 15 of each year beginning January 15, 2015. The 5 1/8% Senior Notes are unsecured obligations and will rank equally in right of payment with our existing and future unsecured senior indebtedness. The 5 1/8% Senior Notes are guaranteed by each of our domestic subsidiaries that guarantees our New Credit Agreement. We may redeem up to 35% of the 5 1/8% Senior Notes at any time prior to July 15, 2017 at a certain specified price from the proceeds of one or more equity offerings. In

Table of Contents

addition, we may redeem the 5 $\frac{1}{8}$ % Senior Notes at any time prior to July 15, 2019 at make whole redemption prices and after such date at certain specified redemption prices.

We received total proceeds from these borrowings of \$6,250 million, \$4,500 million from the issuance of the New Term Loans and \$1,750 million from the issuance of the 5 $\frac{1}{8}$ % Senior Notes. We used a portion of the proceeds to pay off the total outstanding principal balances under our then existing Senior Secured Credit Facilities plus accrued interest totaling \$5,362.4 million and in addition, to purchase pursuant to a cash tender offer \$483.1 million of the outstanding principal balances of our \$775 million 6 $\frac{3}{8}$ % Senior Notes plus accrued interest and cash tender premium totaling \$512.4 million. The total amount paid for the 6 $\frac{3}{8}$ % Senior Notes from the cash tender offer was \$1,051.25 per 1,000 of principal amount of the 6 $\frac{3}{8}$ % Senior Notes, which resulted in our paying a cash tender premium of \$24.8 million for the redemption of this portion of the 6 $\frac{3}{8}$ % Senior Notes. We also incurred an additional \$81.6 million in fees, discounts and other professional expenses associated with these transactions.

In July 2014, we also purchased an additional \$0.188 million principal amount of the 6 $\frac{3}{8}$ % Senior Notes plus accrued interest totaling \$0.194 million pursuant to the cash tender offer at a price of \$1,021.25 per 1,000 of principal amount of the 6 $\frac{3}{8}$ % Senior Notes, which resulted in our paying an additional cash tender premium of \$0.004 million.

In addition, in July 2014, we redeemed the remaining outstanding principal balance of the 6 $\frac{3}{8}$ % Senior Notes of \$291.7 million at a redemption price of \$1,047.81 per 1,000 of principal amount of the 6 $\frac{3}{8}$ % Senior Notes plus accrued interest and a redemption premium which totaled \$310.0 million. This resulted in an additional redemption premium of \$14.0 million being recorded as debt refinancing charges.

As a result of these transactions, we recorded debt refinancing charges of \$97.5 million that consist of the cash tender premiums, the redemption premium, the write-off of existing deferred financing costs, the write-off of certain new refinancing costs, other professional fees and the losses associated with the termination of several of our interest rate swap agreements.

In addition, as a result of these transactions, we terminated \$1,137.5 million notional amounts of amortizing swaps and also terminated \$600.0 million of forward swaps during June 2014, that resulted in our recognizing a loss of \$3.1 million, of which \$3.0 million was previously recorded in other comprehensive income due to our previously outstanding principal debt being paid-off as described above, and as a result of future forecasted transactions that are no longer probable. The loss is included as a component of our debt refinancing charges. During the six months ended June 30, 2014, we recognized debt expense of \$6.1 million from these swaps.

As of June 30, 2014, we maintain several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts of these swap agreements totaling \$878.7 million. These agreements have the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our New Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the New Term Loan A margin of 1.75%. The overall weighted average effective interest rate also includes the effects of \$121.3 million of unhedged New Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 1.75%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the six months ended June 30, 2014, we recognized debt expense of \$1.6 million from these swaps. As of June 30, 2014, the total fair value of these swap agreements was a net asset of approximately \$0.8 million. We estimate that approximately \$2.7 million of existing unrealized pre-tax losses in other comprehensive income at June 30, 2014 will be reclassified into income over the next twelve months.

As of June 30, 2014, we maintain several interest rate cap agreements that were entered into in March 2013 with notional amounts totaling \$2,735 million on our New Term Loan B debt. These agreements have the economic effect

of capping the LIBOR variable component of our interest rate at a maximum of 2.50% on an

Table of Contents

equivalent amount of our New Term Loan B. During the six months ended June 30, 2014, we recognized debt expense of \$1.2 million from these caps. The cap agreements expire on September 30, 2016. As of June 30, 2014, the total fair value of these cap agreements was an asset of approximately \$2.7 million. During the six months ended June 30, 2014, we recorded a loss of \$4.9 million in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

As of June 30, 2014, we also maintain five other interest rate cap agreements with notional amounts totaling \$1,250 million. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our New Term Loan B debt. However, as a result of the interest rate cap agreements that were entered into in March 2013, as described above, these interest rate cap agreements became ineffective cash flow hedges and as a result any changes in the fair value associated with these interest rate cap agreements will be charged to income. During the six months ended June 30, 2014, we recognized debt expense of \$1.8 million from these caps. The cap agreements expire on September 30, 2014.

As a result of an embedded LIBOR floor on the New Term Loan B debt agreement and the swap and cap agreements, our overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.51%, based upon the current margins in effect of 1.75% for the New Term Loan A and 2.75% for the New Term Loan B, as of June 30, 2014.

As of June 30, 2014, the interest rate on our New Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date. Furthermore, the interest rate on \$2,735 million of our New Term Loan B is subject to an interest rate cap if LIBOR should rise above 2.50%. Interest rates on our senior notes are fixed by their terms. The LIBOR variable component of our interest rates on the majority of our New Term Loan A is economically fixed as a result of interest rate swaps.

Our overall weighted average effective interest rate during the second quarter of 2014 was 4.85% and as of June 30, 2014 was 4.56%.

As of June 30, 2014, we had undrawn revolving credit facilities totaling \$1,000 million of which approximately \$83 million was committed for outstanding letters of credit. In addition, HCP has an outstanding letter of credit of approximately \$1 million that is secured by a certificate of deposit.

We believe that we will have sufficient liquidity and will generate significant operating cash flows to fund our scheduled debt service and other obligations for the foreseeable future, including the next 12 months, under the terms of our debt agreements. Our primary sources of liquidity are cash from operations and cash from borrowings.

Goodwill

HCP's current and expected future operating results have eroded recently, primarily as a result of reductions in its Medicare Advantage reimbursement rates. As a result, we have determined that two of HCP's reporting units, HCP California and HCP Nevada, are at risk of goodwill impairment. HCP California and HCP Nevada have goodwill of \$2,511 million and \$518 million respectively.

We obtained preliminary third-party valuations of these two businesses as of June 30, 2014, noting that the estimated fair values of HCP California and HCP Nevada exceed their total carrying values by approximately 6.0% and 10.9%, respectively. Further reductions in HCP's reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future.

For example, a sustained, long-term reduction of 3% in operating income for HCP California and HCP Nevada could reduce their estimated fair values by up to 3.1% and 2.9%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California and HCP Nevada by up to 7.7% and 6.1%, respectively.

Table of Contents

During the first six months of 2014, we did not record any goodwill impairment charges. Except as described above, none of the goodwill associated with our various other reporting units was considered at risk of impairment as of June 30, 2014. Since the dates of our last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in circumstances that have affected our businesses. However, these did not cause management to believe it is more likely than not that the fair value of any of its reporting units would be less than its carrying amount.

Stock-based compensation awards

Stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares, or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. During the six months ended June 30, 2014, we granted 1,247,927 stock-settled stock appreciation rights with an aggregate grant-date fair value of \$20.0 million and a weighted-average expected life of approximately 4.2 years and 315,799 stock units with an aggregate grant-date fair value of \$22.8 million and a weighted-average expected life of approximately 3.4 years, 105,360 of which are performance-based.

Long-term incentive compensation

Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to our dialysis and related lab services business, our HCP business, corporate support costs, and the ancillary services and strategic initiatives.

Long-term incentive compensation costs of \$29.9 million in the second quarter of 2014 increased by approximately \$6.8 million as compared to the first quarter of 2014 and increased by approximately \$9.8 million as compared to the second quarter of 2013. The increase in long-term incentive compensation in the second quarter of 2014 as compared to the first quarter of 2014 was primarily due to an increase in the fair value of LTIP awards during the quarter that contributed additional expense as well as the additional expense from LTIP awards granted during the second quarter. The increase in long-term incentive compensation in the second quarter of 2014 as compared to the second quarter of 2013 was primarily due to an increase in the fair value of LTIP awards that contributed expense to this period and additional expense from the LTIP grants awarded during the quarter.

As of June 30, 2014, there was \$162.4 million of total estimated unrecognized compensation cost for outstanding LTIP awards, including \$99.3 million related to stock-based compensation arrangements under our equity compensation and stock purchase plans. We expect to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.1 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.4 years.

Off-balance sheet arrangements and aggregate contractual obligations

In addition to the debt obligations reflected on our balance sheet, we have commitments associated with operating leases and letters of credit, as well as potential obligations associated with our equity investments in nonconsolidated businesses and to dialysis centers that are wholly-owned by third parties. Substantially all of our U.S. dialysis facilities are leased. We have potential obligations to purchase the noncontrolling interests held by third parties in several of our majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in

each specific put provision. If these put provisions were exercised, we would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to us, which is

Table of Contents

intended to approximate fair value. The methodology we use to estimate the fair values of noncontrolling interests subject to put provisions assumes either the higher of a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from our current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests. The amount of noncontrolling interests subject to put provisions that contractually employ a predetermined multiple of earnings rather than fair value are immaterial. For additional information see Note 10 to the condensed consolidated financial statements.

We also have certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which we own a minority equity investment as well as to physician-owned vascular access clinics that we operate under management and administrative services agreements.

The following is a summary of these contractual obligations and commitments as of June 30, 2014 (in millions):

	Remainder of 2014	1-3 years	4-5 years	After 5 years	Total
Scheduled payments under contractual obligations:					
Long-term debt	\$ 344	\$ 343	\$ 858	\$ 7,089	\$ 8,634
Interest payments on the senior notes	63	541	426	822	1,852
Interest payments on the New Term Loan B ⁽¹⁾	65	305	239	234	843
Interest payments on the New Term Loan A ⁽²⁾	10	44	28		82
Capital lease obligations	4	26	23	130	183
Operating leases	167	1,007	493	714	2,381
	\$ 653	\$ 2,266	\$ 2,067	\$ 8,989	\$ 13,975
Potential cash requirements under existing commitments:					
Letters of credit	\$ 84	\$	\$	\$	\$ 84
Noncontrolling interests subject to put provisions	424	131	79	126	760
Non-owned and minority owned put provisions	31				31
Pay-fixed swaps potential obligations	3				3
Operating capital advances	2				2
	\$ 544	\$ 131	\$ 79	\$ 126	\$ 880

(1) Assuming no changes to LIBOR-based interest rates as the New Term Loan B currently bears interest at LIBOR (floor of 0.75%) plus an interest rate margin of 2.75%.

- (2) Based upon current LIBOR-based interest rates in effect at June 30, 2014 plus an interest rate margin of 1.75% for the New Term Loan A.

The pay-fixed swap obligations represent the estimated fair market values of our interest rate swap agreements that are based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs and other current market conditions that existed as of June 30, 2014. This amount represents the estimated potential obligation that we would be required to pay based upon the

Table of Contents

estimated future settlement of each specific tranche over the term of the swap agreements, assuming no future changes in the forward yield curve. The actual amount of our obligation associated with these swaps in the future will depend upon changes in the LIBOR-based interest rates that can fluctuate significantly depending upon market conditions, and other relevant factors that can affect the fair market value of these swap agreements.

In addition to the above commitments, we are obligated to purchase a certain amount of our hemodialysis products and supplies at fixed prices through 2015 from Gambro Renal Products, Inc. (Gambro) in connection with a product supply agreement with Gambro. Our total expenditures for the six months ended June 30, 2014 on such products were approximately 2% of our total U.S. dialysis operating costs. In January 2010, we entered into an agreement with Fresenius which originally committed us to purchase a certain amount of dialysis equipment, parts and supplies from them through 2013. However, this agreement has been extended through 2015. Our total expenditures for the six months ended June 30, 2014 on such dialysis products were approximately 2% of our total U.S. dialysis operating costs. The actual amount of purchases in future years from Gambro Renal Products and Fresenius will depend upon a number of factors, including the operating requirements of our centers, the number of centers we acquire, growth of our existing centers, and in the case of the Product Supply Agreement, Gambro Renal Products' ability to meet our needs.

In November 2011, we entered into a seven year sourcing and supply agreement with Amgen USA Inc. that expires on December 31, 2018. Under the terms of the agreement, we will purchase EPO in amounts necessary to meet no less than 90% of our requirements for erythropoiesis stimulating agents (ESAs). The actual amount of EPO that we will purchase from Amgen will depend upon the amount of EPO administered during dialysis as prescribed by physicians and the overall number of patients that we serve.

Settlements of approximately \$74 million of existing income tax liabilities for unrecognized tax benefits including interest, penalties and other long-term tax liabilities are excluded from the above table as reasonably reliable estimates of their timing cannot be made.

Supplemental information concerning certain Physician Groups and unrestricted subsidiaries

The following information is presented as supplemental data as required by the indentures governing our senior notes.

We provide services to certain physician groups that, while consolidated in our financial statements for financial reporting purposes, are not subsidiaries of or owned by us, do not constitute "Subsidiaries", as defined in the indentures governing our outstanding senior notes, and do not guarantee those senior notes. In addition, we have entered into management agreements with these physician groups pursuant to which we receive management fees from the physician groups.

As of June 30, 2014, if these physician groups were not consolidated in our financial statements, our consolidated indebtedness would have been approximately \$8,800 million, our consolidated other liabilities (excluding indebtedness) would have been approximately \$3,151 million and our consolidated assets would have been approximately \$17,451 million. If these physician groups were not consolidated in our financial statements (i) for the three months ended June 30, 2014, our consolidated total net revenues (including approximately \$145 million of management fees payable to us), consolidated operating income and consolidated net income would be reduced by approximately \$253 million, \$12 million, and \$6 million, respectively, and (ii) for the six months ended June 30, 2014, our consolidated total net revenues (including approximately \$302 million of management fees payable to us), consolidated operating income and consolidated net income would be reduced by approximately \$494 million, \$20 million, and \$9 million, respectively.

In addition, we own a 67% equity interest in California Medical Group Insurance (CMGI). CMGI is an Unrestricted Subsidiary, as defined in the indentures governing our outstanding senior notes, and does not guarantee those senior notes. Our equity interest in CMGI is accounted for under the equity method of

Table of Contents

accounting, meaning that, although CMGI is not consolidated in our financial statements for financial reporting purposes, our consolidated income statement reflects our pro rata share of CMGI's net loss as equity investment loss.

For the three months ended June 30, 2014, our equity investment income attributable to CMGI was income of approximately \$0.016 million, and for the three months ended June 30, 2014, excluding our equity investment income attributable to CMGI, our consolidated operating income and consolidated net income would be decreased by approximately \$0.016 million and \$0.009 million, respectively. For the six months ended June 30, 2014, our equity investment loss attributable to CMGI was a loss of approximately \$0.2 million, and for the six months ended June 30, 2014, excluding our equity investment loss attributable to CMGI, our consolidated operating income and consolidated net income would be increased by approximately \$0.2 million and \$0.1 million, respectively. See Note 20 to the condensed consolidated financial statements for further details.

Item 3. Quantitative and Qualitative Disclosures about Market Risk
Interest rate sensitivity

The tables below provide information about our financial instruments that are sensitive to changes in interest rates. The table below presents principal repayments and current weighted average interest rates on our debt obligations as of June 30, 2014. The variable rates presented reflect the weighted average LIBOR rates in effect for all debt tranches plus interest rate margins in effect as of June 30, 2014. The New Term Loan A margin in effect is 1.75% at June 30, 2014, and along with the revolving line of credit are subject to adjustment depending upon changes in certain of our financial ratios, including a leverage ratio. The New Term Loan B currently bears interest at LIBOR (floor of 0.75%) plus an interest rate margin of 2.75%.

	Expected maturity date								Average interest rate	Fair value
	2014	2015	2016	2017	2018	2019	Thereafter	Total		
(dollars in millions)										
Long term debt:										
Fixed rate	\$ 322	\$ 60	\$ 51	\$ 53	\$ 52	\$ 51	\$ 7,218	\$ 7,807	4.85%	\$ 7,995
Variable rate	\$ 26	\$ 52	\$ 64	\$ 89	\$ 102	\$ 676	\$ 1	\$ 1,010	1.90%	\$ 1,010

	Notional amount	Contract maturity date				Pay fixed	Receive variable	Fair value
		2014	2015	2016	2017 2018			
(dollars in millions)								
Swaps:								
Pay-fixed rate	\$ 879	\$ 24	\$ 95	\$ 760	\$	0.49% to 0.52%	LIBOR	\$ 0.8
Cap agreements	\$ 2,735	\$	\$	\$ 2,735	\$		LIBOR above 2.50%	\$ 2.7

Our Senior Secured Credit Facilities, which include the New Term Loan A and the New Term Loan B, consist of various individual tranches of debt that can range in maturity from one month to twelve months (currently, all tranches are one month in duration). For the New Term Loan A, each tranche bears interest at a LIBOR rate that is determined by the duration of such tranche plus an interest rate margin. The LIBOR variable component of the interest rate for each tranche is reset as such tranche matures and a new tranche is established. LIBOR can fluctuate significantly depending upon conditions in the credit and capital markets. However, the LIBOR variable component of the interest

rate for the majority of the New Term Loan A is economically fixed as a result of our swap agreements, as described below.

The New Term Loan B is subject to a LIBOR floor of 0.75%. Because actual LIBOR, as of June 30, 2014, was lower than this embedded LIBOR floors, the interest rate on the New Term Loan B is treated as effectively fixed for purposes of the table above. We have included the New Term Loan B in the fixed rate totals in the table above until such time as the actual LIBOR-based variable component of our interest rate exceeds 0.75% on

Table of Contents

the New Term Loan B. At such time, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate for the New Term Loan B, but limited to a maximum LIBOR rate of 2.50% on \$2,735 million of outstanding principal debt on the New Term Loan B as a result of the interest rate cap agreements, as described below. The remaining \$765 million outstanding principal balance of the New Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 0.75%.

As of June 30, 2014, we maintain several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts of these swap agreements totaling \$878.7 million. These agreements have the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our New Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the New Term Loan A margin of 1.75%. The overall weighted average effective interest rate also includes the effects of \$121.3 million of unhedged New Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 1.75%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the six months ended June 30, 2014, we recognized debt expense of \$1.6 million from these swaps. As of June 30, 2014, the total fair value of these swap agreements was a net asset of approximately \$0.8 million. We estimate that approximately \$2.7 million of existing unrealized pre-tax losses in other comprehensive income at June 30, 2014 will be reclassified into income over the next twelve months.

As of June 30, 2014, we maintain several interest rate cap agreements that were entered into in March 2013 with notional amounts totaling \$2,735 million on our New Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 2.50% on an equivalent amount of our New Term Loan B. During the six months ended June 30, 2014, we recognized debt expense of \$1.2 million from these caps. The cap agreements expire on September 30, 2016. As of June 30, 2014, the total fair value of these cap agreements was an asset of approximately \$2.7 million. During the six months ended June 30, 2014, we recorded a loss of \$4.9 million in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

As of June 30, 2014, we also maintain five other interest rate cap agreements with notional amounts totaling \$1,250 million. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our New Term Loan B debt. However, as a result of the interest rate cap agreements that were entered into in March 2013, as described above, these interest rate cap agreements became ineffective cash flow hedges and as a result any changes in the fair value associated with these interest rate cap agreements will be charged to income. During the six months ended June 30, 2014, we recognized debt expense of \$1.8 million from these caps. The cap agreements expire on September 30, 2014.

As a result of an embedded LIBOR floor on the New Term Loan B debt agreement and the swap and cap agreements, our overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.51%, based upon the current margins in effect of 1.75% for the New Term Loan A and 2.75% for the New Term Loan B, as of June 30, 2014.

As of June 30, 2014, the interest rate on our New Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date. Furthermore, the interest rate on \$2,735 million of our New Term Loan B is subject to an interest rate cap if LIBOR should rise above 2.50%. Interest rates on our senior notes are fixed by their terms. The LIBOR variable component of our interest rate on the majority of our New Term Loan A is economically fixed as a result of interest rate swaps.

Our overall weighted average effective interest rate for the second quarter of 2014 was 4.85% and as of June 30, 2014 was 4.56%.

Table of Contents

Item 4. *Controls and Procedures*

Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosures.

At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures in accordance with the Exchange Act requirements. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective for timely identification and review of material information required to be included in the Company's Exchange Act reports, including this report on Form 10-Q. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.

There has not been any change in the Company's internal control over financial reporting during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

The information in Note 9 of the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report is incorporated by this reference in response to this item.

Item 1A. Risk Factors

A restated description of the risk factors associated with our business is set forth below. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013. The risks discussed below are not the only ones facing our business. Please read the cautionary notice regarding forward-looking statements under the heading Management's Discussion and Analysis of Financial Condition and Results of Operations .

Risk factors related to our U.S. dialysis and related lab services, ancillary services and strategic initiatives:

If the average rates that commercial payors pay us decline significantly, it would have a material adverse effect on our revenues, earnings and cash flows.

Approximately 33% of our dialysis and related lab services revenues for the six months ended June 30, 2014, were generated from patients who have commercial payors as their primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. We continue to experience downward pressure on some of our commercial payment rates as a result of general conditions in the market, recent and future consolidations among commercial payors, increased focus on dialysis services and other factors. There is no guarantee that commercial payment rates will not be materially lower in the future.

We are continuously in the process of negotiating our existing or potentially new agreements with commercial payors who tend to be aggressive in their negotiations with us. Sometimes many significant agreements are up for renewal or being renegotiated at the same time. In the event that our continual negotiations result in overall commercial rate reductions in excess of overall commercial rate increases, the cumulative effect could have a material adverse effect on our financial results. Consolidations have significantly increased the negotiating leverage of commercial payors. Our negotiations with payors are also influenced by competitive pressures, and we may experience decreased contracted rates with commercial payors or experience decreases in patient volume as our negotiations with commercial payors continue. In addition to downward pressure on contracted commercial payor rates, payors have been attempting to impose restrictions and limitations on non-contracted or out-of-network providers, and in some circumstances designate our centers as out-of-network providers. Rates for out-of-network providers are on average higher than rates for in-network providers. We believe commercial payors have or will begin to restructure their benefits to create disincentives for patients to select or remain with out-of-network providers and to decrease payment rates for out-of-network providers. Decreases in out-of-network rates and restrictions on out-of-network access, our turning away new patients in instances where we are unable to come to agreement on rates, or decreases in contracted

rates could result in a significant decrease in our overall revenues derived from commercial payors. If the average rates that commercial payors pay us decline significantly, or if we see a decline in commercial patients, it would have a material adverse effect on our revenues, earnings and cash flows. For additional details regarding specific risks we face regarding regulatory changes that could result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates, see the discussion of individual and small group health plans in the risk factor below under the heading Health care reform could substantially reduce our revenues, earnings and cash flows.

Table of Contents**If the number of patients with higher-paying commercial insurance declines, then our revenues, earnings and cash flows would be substantially reduced.**

Our revenue levels are sensitive to the percentage of our patients with higher-paying commercial insurance coverage. A patient's insurance coverage may change for a number of reasons, including changes in the patient's or a family member's employment status. Currently, for a patient covered by an employer group health plan, Medicare generally becomes the primary payor after 33 months, or earlier, if the patient's employer group health plan coverage terminates. When Medicare becomes the primary payor, the payment rate we receive for that patient decreases from the employer group health plan rate to the lower Medicare payment rate. We have seen an increase in the number of patients who have government-based programs as their primary payors which we believe is largely a result of improved mortality and recent economic conditions which have a negative impact on the percentage of patients covered under commercial insurance plans. To the extent there are sustained or increased job losses in the U.S., independent of whether general economic conditions might be improving, we could experience a continued decrease in the number of patients covered under commercial plans. We could also experience a further decrease if changes to the healthcare regulatory system result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates. In addition, our continuous process of negotiations with commercial payors under existing or potentially new agreements could result in a decrease in the number of patients under commercial plans to the extent that we cannot reach agreement with commercial payors on rates and other terms, resulting in termination or non-renewals of existing agreements or our inability to enter into new ones. If there is a significant reduction in the number of patients under higher-paying commercial plans relative to government-based programs that pay at lower rates, it would have a material adverse effect on our revenues, earnings and cash flows.

Changes in the structure of and payment rates under the Medicare ESRD program, including the American Taxpayer Relief Act of 2012, the Budget Control Act of 2011 and other healthcare reform initiatives, could substantially reduce our revenues, earnings and cash flows.

Approximately 47% of our dialysis and related lab services revenues for the six months ended June 30, 2014 was generated from patients who have Medicare as their primary payor. For patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment, including pharmaceuticals that were historically separately reimbursed to the dialysis providers, such as Epogen (EPO), vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered or additional services performed. Most lab services that used to be paid directly to laboratories are also included in the bundled payment. The bundled payment rate is also adjusted for certain patient characteristics, a geographic usage index and certain other factors.

The current bundled payment system presents certain operating, clinical and financial risks, which include:

Risk that our rates are reduced by CMS. CMS issued the 2014 final rule for the ESRD PPS, which phases in over three to four years the 12% cut mandated by ATRA. Although no reimbursement reduction is expected in 2014 or 2015 under the final ESRD PPS rule, it is anticipated that future reductions will occur no later than 2017. However, the recent Protecting Access to Medicare Act that was passed on March 31, 2014 further modified the reduction to only 1.25% in 2016 and 2017, and 1% in 2018. While this modification eases reimbursement pressure, future legislative actions could have the opposite effect. CMS recently issued the 2015 proposed rule for the ESRD PPS, which was published in the Federal Register on July 11, 2014. The proposed rule, which may change before it is finalized, would increase payments to dialysis facilities

modestly by 0.3% to 0.5%, although rural facilities would receive a decrease of 0.5%. Uncertainty about future payment rates remain a material risk to our business.

Risk that increases in our operating costs will outpace the Medicare rate increases we receive. We expect to continue experiencing increases in operating costs that are subject to inflation, such as labor and supply costs, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the bundled payment rate system.

Table of Contents

Risk of federal budget sequestration cuts. As a result of the Budget Control Act of 2011 (BCA) and subsequent activity in Congress, a \$1.2 trillion sequester (across-the-board spending cuts) in discretionary programs took effect on March 1, 2013. In particular, a 2% reduction to Medicare payments took effect on April 1, 2013, which was recently extended through 2014 and 2015 by a two-year funding bill signed into law on December 26, 2013. The across-the-board spending cuts pursuant to the sequester have affected and will continue to adversely affect our revenues, earnings and cash flows.

Risk that we may not be able to comply with the CMS ESRD Quality Incentive Program (QIP) requirements. Beginning in payment year 2016, CMS proposed to adopt two new clinical and reporting measures, continue using six existing clinical and reporting measures, revise two existing clinical and reporting measures, and expand one existing reporting measure. The final rule establishes calendar year 2014 as the performance period for all of the quality measures. The July 11, 2014 proposed rule further modifies the QIP by removing hemoglobin as a measurable indicator and adding hospital readmission as a reporting measure. CMS proposes to have a total of eleven clinical measures and five reporting measures in 2018. The QIP continues to evolve and undergo material changes. To the extent we are not able to meet CMS's quality measures, it could have a material adverse effect on our revenues, earnings and cash flows.

For additional details regarding the risks we face for failing to adhere to our Medicare and Medicaid regulatory compliance obligations, see the risk factor below under the heading "If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings, cash flows and stock price."

Health care reform could substantially reduce our revenues, earnings and cash flows.

We cannot predict how employers, private payors or persons buying insurance might react to the changes brought on by broad U.S. health care reform legislation or what form many of these regulations will take before implementation.

The health care reform legislation introduced health care insurance exchanges which provide a marketplace for eligible individuals and small employers to purchase health care insurance. Although we cannot predict the short or long term effects of these measures, we believe the health care insurance exchanges could result in a reduction in patients covered by commercial insurance or an increase of patients covered through the exchanges under more restrictive commercial plans with lower reimbursement rates. To the extent that the implementation of such exchanges results in a reduction in patients covered by commercial insurance or a reduction in reimbursement rates for our services from commercial and/or government payors, our revenues, earnings and cash flows could be adversely affected.

In addition, the health care reform legislation introduced severe penalties for the knowing and improper retention of overpayments collected from government payors and reduced the timeline to file Medicare claims. As a result, we made significant initial investments in new resources to accelerate the time it takes us to identify and process overpayments and we deployed significant resources to reduce our timeline and improve our claims processing methods to ensure that our Medicare claims are filed in a timely fashion. We may be required to make additional investments in the future. Failure to timely identify and return overpayments may result in significant additional penalties, which may have a negative impact on our revenues, earnings and cash flows. Failure to file a claim within the one year window could result in payment denials, adversely affecting our revenues, earnings and cash flows.

The health care reform legislation also added several new tax provisions that, among other things, impose various fees and excise taxes, and limit compensation deductions for health insurance providers and their affiliates. These rules could negatively impact our cash flow and tax liabilities.

Table of Contents

The CMS Center for Medicare & Medicaid Innovation (Innovation Center) is currently working with various healthcare providers to develop and implement ACOs and other innovative models of care for Medicare and Medicaid beneficiaries. We are currently uncertain of the extent to which these models of care, including ACOs, Bundled Payments for Care Improvement Initiative, Comprehensive ESRD Care Model (which includes the development of ESCOs), the Comprehensive Primary Care Initiative, the Duals Demonstration, or other models, will impact the health care market. Our U.S. dialysis business may choose to participate in one or several of these models either as a partner with other providers or independently. We are currently seeking to participate in the Comprehensive ESRD Care Model with the Innovation Center. Even if we do not participate in this or other programs, some of our patients may be assigned to a program, in which case the quality and cost of care that we furnish will be included in an ACO's or other programs' calculations. As new models of care emerge, we may be at risk for losing our Medicare patient base, which would have a materially adverse effect on our revenues, earnings and cash flow. Other initiatives in the government or private sector may arise, including the development of models similar to ACOs, IPAs and integrated delivery systems or evolutions of those concepts which could adversely impact our business.

CMS instituted new screening procedures which we expect will delay the Medicare contractor approval process, potentially causing a delay in reimbursement. We anticipate the new screening and enrollment requirements will require additional personnel and financial resources and will potentially delay the enrollment and revalidation of our centers which in turn will delay payment. These delays may negatively impact our revenues, earnings and cash flows.

Other reform measures allow CMS to place a moratorium on new enrollment of providers and to suspend payment to providers upon a credible allegation of fraud from any source. These types of reform measures, as well as other measures, could adversely impact our revenues, earnings and cash flows depending upon the scope and breadth of the implementing regulations.

There is also a considerable amount of uncertainty as to the prospective implementation of the federal healthcare reform legislation and what similar measures might be enacted at the state level. The enacted reforms as well as future legislative changes could have a material adverse effect on our results of operations, including lowering our reimbursement rates and increasing our expenses.

Changes in state Medicaid or other non-Medicare government-based programs or payment rates could reduce our revenues, earnings and cash flows.

Approximately 20% of our dialysis and related lab services revenues for the six months ended June 30, 2014 was generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs (VA), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, we may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs. For example, certain state Medicaid programs and the VA have recently considered, proposed or implemented payment rate reductions.

The VA recently adopted Medicare's bundled PPS pricing methodology for any veterans receiving treatment from non-VA providers under a new national contracting initiative. Since we are a non-VA provider, these reimbursements are now tied to a percentage of Medicare reimbursement, and we have additional exposure to any dialysis reimbursement changes made by CMS. Approximately 2% of our dialysis and related lab services revenues for the six months ended June 30, 2014 was generated by the VA. In 2013, we entered into a five-year Nationwide Dialysis Services contract with the VA which is subject to one-year renewal periods, consistent with all provider agreements with the VA under this contract. These agreements provide for the right of the VA to terminate the agreements without cause on short notice. Should the VA not renew or cancel these agreements for any reason, we may cease

accepting patients under this program and may be forced to close centers, which could adversely affect our revenues, earnings and cash flows.

Table of Contents

State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these payment systems are poorly defined and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these payment systems are implemented without any adjusters and claims processing changes, Medicaid payments will be substantially reduced and the costs to submit such claims may increase, which will have a negative impact on our revenues, earnings and cash flows. In addition, some state Medicaid program eligibility requirements mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be denied coverage under these programs, resulting in decreased patient volumes and revenue. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs could reduce the rates paid by these programs for dialysis and related services, delay the receipt of payment for services provided, and further limit eligibility for coverage which could adversely affect our revenues, earnings and cash flows.

Changes in clinical practices, payment rates or regulations impacting EPO and other pharmaceuticals could adversely affect our operating results, reduce our revenues, earnings and cash flows and negatively impact our ability to care for patients.

Medicare bundles EPO into the prospective payment system such that dosing variations do not change the amount paid to a dialysis facility. Although some Medicaid programs and other payors suggest movement towards a bundled payment system inclusive of EPO, some non-Medicare payors continue to pay for EPO separately from the treatment rate. The administration of EPO and other pharmaceuticals that are separately billable accounted for approximately 3% of our dialysis and related lab services revenues for the six months ended June 30, 2014, with EPO alone accounting for approximately 2% of our dialysis and related lab services revenues during that period. Changes in physician clinical practices that result in further decreased utilization of prescribed pharmaceuticals or changes in payment rates for those pharmaceuticals could reduce our revenues, earnings and cash flows.

Evaluations on the utilization and reimbursement for ESAs, which have occurred in the past and may occur in the future, and related actions by the U.S. Congress and federal agencies, could result in further restrictions on the utilization and reimbursement for ESAs. Additionally, commercial payors have increasingly examined their administration policies for EPO and, in some cases, have modified those policies. Changes in labeling of EPO and other pharmaceuticals in a manner that alters physician practice patterns or accepted clinical practices, changes in private and governmental payment criteria, including the introduction of EPO administration policies or the conversion to alternate types of administration of EPO or other pharmaceuticals that result in further decreases in utilization of EPO for patients covered by commercial payors could have a material adverse effect on our revenues, earnings and cash flows. Further increased utilization of EPO for patients for whom the cost of EPO is included in a bundled reimbursement rate, or further decreases in reimbursement for EPO and other pharmaceuticals that are not included in a bundled reimbursement rate, could also have a material adverse effect on our revenues, earnings and cash flows.

Additionally, as a result of the current high level of scrutiny and controversy, we may be subject to increased inquiries or audits from a variety of governmental bodies or claims by third parties. Although we believe our anemia management practices and other pharmaceutical administration practices have been compliant with existing laws and regulations, increased inquiries or audits from governmental bodies or claims by third parties would require management's attention, and could result in significant legal expense. Any negative findings could result in substantial financial penalties or repayment obligations, the imposition of certain obligations on and changes to our practices and procedures as well as the attendant financial burden on us to comply with the obligations, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our revenues, earnings and cash flows.

Table of Contents**Changes in EPO pricing could materially reduce our earnings and cash flows and affect our ability to care for our patients.**

Future increases in the cost of EPO without corresponding increases in payment rates for EPO from commercial payors and without corresponding increases in the Medicare bundled rate could have a material adverse effect on our earnings and cash flows and ultimately reduce our income. In November 2011, we entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc., pursuant to which we committed to purchase EPO in amounts necessary to meet no less than 90% of our requirements for ESAs. As long as we meet certain conditions, the agreement limits Amgen's ability to unilaterally increase the price for EPO during the term of the agreement. Our agreement with Amgen for EPO provides for discounted pricing and rebates for EPO. However, some of the rebates are subject to various conditions including, but not limited to, future pricing levels of EPO by Amgen and data submission by us. In addition, the rebates are subject to certain limitations. We cannot predict whether, over the seven year term of the agreement, we will continue to receive the rebates for EPO that we have received in the past, or whether we will continue to achieve the same levels of rebates within that structure as we have historically achieved. In the initial years of the agreement, the total rebate opportunity is less than what was provided in the agreement that expired at the end of 2011; however, the opportunity for us to earn discounts and rebates increases over the term of the agreement. Factors that could impact our ability to qualify for rebates provided for in our agreement with Amgen in the future include, but are not limited to, our ability to track certain data elements. We cannot predict whether we will be able to meet the applicable qualification requirements for receiving rebates. Failure to meet certain targets and earn the specified rebates could have a material adverse effect on our earnings and cash flows.

We are the subject of a number of investigations by the federal government and two private civil suits, any of which could result in substantial penalties or awards against us, the imposition of certain obligations on our practices and procedures, exclusion from future participation in the Medicare and Medicaid programs and possible criminal penalties.

We are the subject of a number of investigations by the federal government. We have received subpoenas or other requests for documents from the federal government in connection with the Vainer private civil suit, the 2010 U.S. Attorney physician relationship investigation, the 2011 U.S. Attorney physician relationship investigation and the 2011 U.S. Attorney Medicaid investigation. Certain current and former members of our Board, as well as executives and other teammates have been subpoenaed to testify before a grand jury in Colorado related to the 2011 U.S. Attorney physician relationship investigation. (See Note 9 to the condensed consolidated financial statements of this report for additional details regarding these matters.)

With respect to the Vainer private civil suit, after investigation, the federal government did not intervene and is not actively pursuing this private civil suit. With respect to the Swoben civil suit, the United States Department of Justice declined to intervene after its review of the allegations contained in the Third Amended Complaint and is not actively pursuing this private civil suit other than its partial intervention for the purpose of settlement with and dismissal of the initial defendant in this proceeding. In each of these private civil suits, a relator filed a complaint against us in federal court under the *qui tam* provisions of the False Claims Act (FCA) (and in the Swoben matter, provisions of the California False Claims Act, as well) and pursued the claims independently after the government declined to intervene. The parties are engaged in active litigation in the Vainer private civil suit. With regard to the Swoben private civil suit, in July 2013, the court granted HCP's motion and dismissed with prejudice all of the claims in the Third Amended Complaint, and in October 2013 the plaintiff filed an appeal of the dismissal, which is currently pending. (See Note 9 to the condensed consolidated financial statements of this report for additional details regarding these matters).

We are cooperating with HHS's OIG and those offices of the U.S. Attorney pursuing the matters mentioned above. In addition, we have agreed to a framework for a global resolution with the United States Attorney's Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The settlement will include the payment of approximately \$389 million, entry into a corporate integrity agreement,

Table of Contents

the appointment of an independent compliance monitor, and the imposition of certain other business restrictions related to a subset of our joint venture arrangements. We have agreed to unwind a limited subset of joint ventures that were created through partial divestiture to nephrologists, and agreed not to enter into this type of partial divestiture joint venture with nephrologists in the future. The final settlement remains subject to negotiation of specific terms, and we can make no assurances as to the final outcome.

If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings, cash flows and stock price.

Our dialysis operations are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations, federal and state anti-kickback laws, the physician self-referral law (Stark Law) and analogous state self-referral prohibition statutes, Federal Acquisition Regulations, the FCA and federal and state laws regarding the collection, use and disclosure of patient health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments.

We endeavor to comply with all legal requirements, however, there is no guarantee that we will be able to adhere to all of the complex government regulations that apply to our business. For example, we have experienced past security breaches with regard to patient health information and there can be no assurance that we will not suffer security breaches in the future. We further endeavor to structure all of our relationships with physicians to comply with state and federal anti-kickback and physician self-referral laws. We utilize considerable resources to monitor the laws and implement necessary changes. However, the laws and regulations in these areas are complex and often subject to varying interpretations. For example, if an enforcement agency were to challenge the level of compensation that we pay our medical directors or the number of medical directors whom we engage, we could be required to change our practices, face criminal or civil penalties, pay substantial fines or otherwise experience a material adverse effect as a result of a challenge to these arrangements. In addition, amendments to the FCA impose severe penalties for the knowing and improper retention of overpayments collected from government payors. These amendments could subject our procedures for identifying and processing overpayments to greater scrutiny. We have made significant investments in new resources to decrease the time it takes to identify and process overpayments and we may be required to make additional investments in the future. An acceleration in our ability to identify and process overpayments could result in us refunding overpayments to government and other payors more rapidly than we have in the past which could have a material adverse effect on our operating cash flows. Additionally, amendments to the federal anti-kickback statute in the health reform law make anti-kickback violations subject to FCA prosecution, including *qui tam* or whistleblower suits.

If any of our operations are found to violate these or other government regulations, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings, cash flows and stock price, including:

Suspension or termination of our participation in government payment programs;

Refunds of amounts received in violation of law or applicable payment program requirements;

Loss of required government certifications or exclusion from government payment programs;

Loss of licenses required to operate health care facilities or administer pharmaceuticals in some of the states in which we operate;

Reductions in payment rates or coverage for dialysis and ancillary services and related pharmaceuticals;

Table of Contents

Fines, damages or monetary penalties for anti-kickback law violations, Stark Law violations, FCA violations, civil or criminal liability based on violations of law, or other failures to meet regulatory requirements;

Enforcement actions by governmental agencies and/or state claims for monetary damages by patients who believe their protected health information has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including Health Insurance Portability and Accountability Act (HIPAA) of 1996;

